Stroke is the third most common cause of death in the United States and the most disabling neurologic disorder. Approximately 700,000 patients suffer from stroke annually. Stroke is a syndrome characterized by the acute onset of a neurological deficit that persists for at least 24 hours, reflecting focal involvement of the central nervous system, and is the result of a disturbance of the cerebral circulation. Its incidence increases with age. Risk factors for stroke include systolic or diastolic hypertension, hypercholesterolemia, cigarette smoking, heavy alcohol consumption, and oral contraceptive use.
Hemorrhagic stroke accounts for 20% of the annual stroke population. Hemorrhagic stroke often occurs due to rupture of an aneurysm or arteriovenous malformation bleeding into the brain tissue, resulting in cerebral infarction. The remaining 80% of the stroke population are ischemic strokes and are caused by occluded vessels that deprive the brain of oxygen-carrying blood. Ischemic strokes are often caused by emboli or pieces of thrombotic tissue that have dislodged from other body sites or from the cerebral vessels themselves to occlude in the narrow cerebral arteries more distally. When a patient presents with neurological symptoms and signs which resolve completely within 1 hour, the term transient ischemic attack (TIA) is used. Etiologically, TIA and stroke share the same pathophysiologic mechanisms and thus represent a continuum based on persistence of symptoms and extent of ischemic insult.
Emboli occasionally form around the valves of the heart or in the left atrial appendage during periods of irregular heart rhythm and then are dislodged and follow the blood flow into the distal regions of the body. Those emboli can pass to the brain and cause an embolic stroke. As will be discussed below, many such occlusions occur in the middle cerebral artery (MCA), although such is not the only site where emboli come to rest.
When a patient presents with neurological deficit, a diagnostic hypothesis for the cause of stroke can be generated based on the patient's history, a review of stroke risk factors, and a neurologic examination. If an ischemic event is suspected, a clinician can tentatively assess whether the patient has a cardiogenic source of emboli, large artery extracranial or intracranial disease, small artery intraparenchymal disease, or a hematologic or other systemic disorder. A head CT scan is often performed to determine whether the patient has suffered an ischemic or hemorrhagic insult. Blood would be present on the CT scan in subarachnoid hemorrhage, intraparenchymal hematoma, or intraventricular hemorrhage.
Traditionally, emergent management of acute ischemic stroke consisted mainly of general supportive care, e.g. hydration, monitoring neurological status, blood pressure control, and/or anti-platelet or anti-coagulation therapy. In 1996, the Food and Drug Administration approved the use of Genentech Inc.'s thrombolytic drug, tissue plasminogen activator (t-PA) or Activase®, for treating acute stroke. A randomized, double-blind trial, the National Institute of Neurological Disorders and t-PA Stroke Study, revealed a statistically significant improvement in stoke scale scores at 24 hours in the group of patients receiving intravenous t-PA within 3 hours of the onset of an ischemic stroke. Since the approval of t-PA, an emergency room physician could, for the first time, offer a stroke patient an effective treatment besides supportive care.
However, treatment with systemic t-PA is associated with increased risk of intracerebral hemorrhage and other hemorrhagic complications. Patients treated with t-PA were more likely to sustain a symptomatic intracerebral hemorrhage during the first 36 hours of treatment. The frequency of symptomatic hemorrhage increases when t-PA is administered beyond 3 hours from the onset of a stroke. Besides the time constraint in using t-PA in acute ischemic stroke, other contraindications include the following: if the patient has had a previous stroke or serious head trauma in the preceding 3 months, if the patient has a systolic blood pressure above 185 mm Hg or diastolic blood pressure above 110 mmHg, if the patient requires aggressive treatment to reduce the blood pressure to the specified limits, if the patient is taking anticoagulants or has a propensity to hemorrhage, and/or if the patient has had a recent invasive surgical procedure. Therefore, only a small percentage of selected stroke patients are qualified to receive t-PA.
Obstructive emboli have also been mechanically removed from various sites in the vasculature for years. Mechanical therapies have involved capturing and removing the clot, dissolving the clot, disrupting and suctioning the clot, and/or creating a flow channel through the clot. One of the first mechanical devices developed for stroke treatment is the MERCI Retriever System (Concentric Medical, Redwood City, Calif.). A balloon-tipped guide catheter is used to access the internal carotid artery (ICA) from the femoral artery. A microcatheter is placed through the guide catheter and used to deliver the coil-tipped retriever across the clot and is then pulled back to deploy the retriever around the clot. The microcatheter and retriever are then pulled back, with the goal of pulling the clot, into the balloon guide catheter while the balloon is inflated and a syringe is connected to the balloon guide catheter to aspirate the guide catheter during clot retrieval. This device has had initially positive results as compared to thrombolytic therapy alone.
Other thrombectomy devices utilize expandable cages, baskets, or snares to capture and retrieve clot. Temporary stents, sometimes referred to as stentrievers or revascularization devices, are utilized to remove or retrieve clot as well as restore flow to the vessel. A series of devices using active laser or ultrasound energy to break up the clot have also been utilized. Other active energy devices have been used in conjunction with intra-arterial thrombolytic infusion to accelerate the dissolution of the thrombus. Many of these devices are used in conjunction with aspiration to aid in the removal of the clot and reduce the risk of emboli. Suctioning of the clot has also been used with single-lumen catheters and syringes or aspiration pumps, with or without adjunct disruption of the clot. Devices which apply powered fluid vortices in combination with suction have been utilized to improve the efficacy of this method of thrombectomy. Finally, balloons or stents have been used to create a patent lumen through the clot when clot removal or dissolution was not possible.
Notwithstanding the foregoing, there remains a need for new devices and methods for treating vasculature occlusions in the body, including acute ischemic stroke and occlusive cerebrovascular disease.
Disclosed herein is a sealed neurovascular extendable catheter having an outer catheter, an inner catheter, and an annular gap between an outer surface of the inner catheter and an inner surface of the outer catheter. The outer catheter has a proximal end and a distal end and the inner catheter has a proximal end and a distal end. The outer catheter is extendable through the outer catheter such that the distal end of the inner catheter is configured to extend beyond the distal end of the outer catheter. The extendable catheter also has a sealing feature positioned between the inner catheter and the outer catheter. The sealing feature is configured to fluidly seal at least a portion of a length of the annular gap. The sealing feature is configured to allow axial translation of the inner catheter relative to the outer catheter.
The sealing feature may have at least one annular protrusion extending around a circumference of the inner catheter. The at least one protrusion may be compliant and may comprise an outer diameter slightly larger than an inner diameter of the outer catheter. The at least one protrusion may be a plurality of protrusions. The at least one protrusion may have a chevron-shape pointing in the distal direction and/or a chevron-shape pointing in the proximal direction. The protrusion may be a skirt-shaped protrusion configured to allow distal fluid flow but not proximal fluid flow through the sealing feature.
The sealing feature may be an expandable bulge surrounding a circumference of the inner catheter. The expandable bulge may have a sealed configuration in which an outer diameter of the expandable bulge seals the annular gap and an unsealed configuration in which the outer diameter of the expandable bulge does not seal the annular gap. The expandable bulge may be mechanically expandable. The expandable bulge may be positioned at a proximal end of the inner catheter. A tension cable may be joined to the expandable bulge at or near a distal end of the expandable bulge and pulling the tension cable proximally may be configured to axially contract and radially expand the expandable bulge. The expandable bulge may be expandable in response to receiving an electric current and/or in response to stimulation by light. The expandable bulge may be a hydrogel. The expandable bulge may be inflatable. The inner catheter may have a proximal spine having a lumen. The lumen may be configured to transmit a stimulus to the expandable bulge for activating the expandable bulge and causing it to expand.
The sealing feature may be an elastic flange positioned at a distal tip of the outer catheter. The elastic flange may have an inner diameter smaller than an outer diameter of the inner catheter.
The sealing feature may be a hub having an expanded diameter. The hub may be positioned at a proximal end of the inner catheter and be configured to form an interference fit with an inner diameter of the outer catheter. The inner catheter may have a proximal spine having a lumen. The lumen may extend through the hub to form a fluid port through the sealing feature. A flushing solution may be delivered through the fluid port to the annular gap in a space distal to the sealing feature.
The sealing feature may have a proximal sliding ring and a distal sliding ring surrounding the inner catheter. Each sliding ring may have an inner annulus configured to form a sliding interference fit around the inner catheter and an outer annulus configured to form a sliding interference fit with an inner diameter of the outer catheter. Each sliding ring may have a plurality of spokes joining the inner annulus and the outer annulus. The sealing feature may have one or more springs surrounding the inner catheter and joining the inner annulus of the proximal sliding ring to the inner annulus of the distal sliding ring and an elastic membrane configured to form a fluid barrier. The elastic membrane may be coupled to the one or more springs such that the fluid barrier circumferentially surrounds the inner catheter and extends from the proximal sliding ring to the distal sliding ring. The sealing feature may further have a ridge feature fixed to an outer surface of the inner catheter. The ridge feature may be positioned between the proximal sliding ring and the distal sliding ring and may be configured to catch and pull the proximal sliding ring in a proximal direction and to catch and pull the distal sliding ring in a distal direction. The one or more springs may force the elastic membrane into compression against an inner surface of the outer catheter to seal the annular gap in an unbiased configuration. Translating the inner catheter to pull one of the sliding rings in a proximal or distal direction may cause the pulled sliding ring to axially extend and radially compress the one or more springs. Radially compressing the one or more springs may cause the elastic membrane to be at least partially retracted from the inner surface of the outer catheter, breaking the fluid seal for a period while the inner catheter is in motion.
The sealing feature may have a large diameter ring surrounding the inner catheter and a small diameter ring surrounding the inner catheter. The large diameter ring may have an inner annulus configured to receive the inner catheter, an outer annulus configured to form a sliding interference fit with an inner diameter of the outer catheter, and a plurality of spokes joining the inner annulus and the outer annulus. The small diameter ring may be positioned either proximally or distally of the large diameter ring and may form a sliding interference fit with an outer surface of the inner catheter. The small diameter ring may have one or more recesses configured to receive one or more key features extending axially along at least a portion of the inner catheter. The one or more recesses may be configured to rotate the small diameter ring with the inner catheter. The sealing feature may also have a torsion spring surrounding the inner catheter and joining the small diameter ring to the large diameter ring and an elastic membrane coupled to the torsion spring. The elastic membrane may be configured to form a fluid barrier circumferentially surrounding the inner catheter and extending from the large diameter ring to the small diameter ring. The torsion spring may force the elastic membrane into compression against an inner surface of the outer catheter to seal the annular gap in an unbiased configuration. Rotating the inner catheter to rotate the small diameter ring may cause the torsion spring to axially extend and radially compress such that elastic membrane is at least partially retracted from the inner surface of the outer catheter, breaking the fluid seal for a period while the inner catheter is in motion.
In another aspect of the present disclosure, disclosed herein is a neurovascular catheter for sealing a blood vessel. The neurovascular catheter has an elongate body having a proximal end and a distal end and a sealing feature configured to fluidly seal an annular gap positioned between an outer surface of the elongate body and the blood vessel. The sealing feature has a compliant annular ring configured to be placed into compression with a wall of the blood vessel without damaging the blood vessel.
The ring may comprise an elastomeric polymer. The ring may be a hydrogel. The hydrogel may be electrosensitive and configured to expand upon receiving an electric current and/or may be photosensitive and configured to expand upon receiving a light stimulus. The hydrogel may be configured to expand upon exposure the intravascular physiological environment. The ring may be inflatable. The outer surface of the elongate body may have a recess for receiving the ring. The ring may be detachable from the elongate body. The ring may be custom-formed to the size of the blood vessel. The neurovascular catheter may further include a replacement ring that is sized differently from the ring and interchangeable with the ring.
Any feature, structure, or step disclosed herein can be replaced with or combined with any other feature, structure, or step disclosed herein, or omitted. Further, for purposes of summarizing the disclosure, certain aspects, advantages, and features of the embodiments have been described herein. It is to be understood that not necessarily any or all such advantages are achieved in accordance with any particular embodiment disclosed herein. No individual aspects of this disclosure are essential or indispensable. Further features and advantages of the embodiments will become apparent to those of skill in the art in view of the Detailed Description which follows when considered together with the attached drawings and claims.
Referring to
The catheters disclosed herein may readily be adapted for use throughout the body wherever it may be desirable to distally advance a low profile distal catheter segment from a larger diameter proximal segment. For example, axially extendable catheter shafts in accordance with the present invention may be dimensioned for use throughout the coronary and peripheral vasculature, the gastrointestinal tract, the urethra, ureters, Fallopian tubes and other lumens and potential lumens, as well. The telescoping structure of the present invention may also be used to provide minimally invasive percutaneous tissue access, such as for diagnostic or therapeutic access to a solid tissue target (e.g., breast or liver or brain biopsy or tissue excision), delivery of laparoscopic tools or access to bones such as the spine for delivery of screws, bone cement or other tools or implants.
The catheter 10 generally comprises an elongate tubular body 16 extending between a proximal end 12 and a distal functional end 14. The length of the tubular body 16 depends upon the desired application. For example, lengths in the area of from about 120 cm to about 140 cm or more are typical for use in femoral access percutaneous transluminal coronary applications. Intracranial or other applications may call for a different catheter shaft length depending upon the vascular access site, as will be understood in the art.
In the illustrated embodiment, the tubular body 16 is divided into at least a fixed proximal section 33 and an axially extendable and retractable distal section 34 separated at a transition 32.
Referring to
The inner diameter of the distal section 34 may be between about 0.030 inches and about 0.112 inches, between about 0.040 inches and about 0.102 inches, between about 0.045 inches and about 0.097 inches, between about 0.050 inches and about 0.092 inches, between about 0.055 inches and about 0.087 inches, between about 0.060 inches and about 0.082 inches, between about 0.062 inches and about 0.080 inches, between about 0.064 inches and about 0.078 inches, between about 0.066 inches and about 0.076 inches, between about 0.068 inches and about 0.074 inches, or between about 0.070 inches and about 0.072 inches.
The inner diameter and the outer diameter of the distal section 34 may be constant or substantially constant along its longitudinal length. The inner diameter may be at least about 0.06 inches, 0.065 inches, 0.07 inches, 0.075 inches, 0.08 inches, or more than 0.08 inches. The outer diameter may be at least about 0.07 inches, 0.075 inches, 0.08 inches, 0.085 inches, 0.09 inches, 0.095 inches, 0.1 inches, or more than 0.1 inches. The total thickness of the sidewall extending between the inner and outer diameter may be at least about 0.005 inches, 0.010 inches, 0.015 inches, 0.02 inches, 0.025 inches, or more than 0.025 inches. For example, the distal section may 34 may have an inner diameter of about 0.071 inches and an outer diameter of about 0.083 inches. Alternatively, the distal section 34 may be tapered near its distal end. A larger lumen (internal diameter) may increase the applied aspiration force through the distal end of the distal section 34. A smaller outer diameter may provide better catheter trackability and/or may better enable the catheter to reach more distal anatomy (e.g. neuroanatomy), as the tapered distal end may be better accommodated in smaller blood vessels. The inner and outer diameters of the distal section 34 may be correlated in order to maintain a sufficient sidewall thickness that provides sufficient structural integrity to the catheter. The distal section 34 may be tapered at less than or equal to about 5 cm, about 10 cm, about 15 cm, about 20 cm, about 23 cm, about 25 cm, about 30 cm, about 31 cm, about 35 cm, about 40 cm, about 45 cm, about 50 cm, about 60 cm, or about 70 cm from its distal end. In some embodiments, the taper may be positioned between about 25 cm and about 35 cm from the distal end of the distal section 34. In some embodiments, the taper may be positioned between about 15 cm and about 25 cm from the distal end of the distal section 34.
The inner diameter of the distal section 34 may be tapered or decreased in the distal direction near the distal end to an internal diameter that is less than or equal to about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, or about 50% of the adjacent, untapered internal diameter. In some embodiments, the internal diameter of the tapered distal section 34 may be between about 50% and about 70% of the adjacent, untapered internal diameter. For example, the untapered internal diameter at the proximal end of the distal section 34 may be about 0.071 inches and the tapered internal diameter at the distal end of the distal section 34 may be about 0.035 inches, 0.045 inches, or 0.055 inches. The inner diameter of the distal section 34 may be tapered or increased near the distal end by greater than or equal to about 102%, 104%, 106%, 108%, or more of the internal diameter just proximal to a transition into the taper. The tapered inner diameter of the distal section 34 may be less than or equal to about 0.11 inches, about 0.1 inches, about 0.090 inches, about 0.080 inches, about 0.070 inches, about 0.065 inches, about 0.060 inches, about 0.055 inches, about 0.050 inches, about 0.045 inches, about 0.040 inches, about 0.035 inches, about 0.030 inches, about 0.025 inches, about 0.020 inches, about 0.015 inches, or about 0.010 inches. The taper in the outer diameter of the tapered portion of the distal section 34 may be matched to maintain a constant thickness of the sidewall. Alternatively, the sidewall may be thinner along the tapered portion. For instance, the sidewall may be no greater than 95%, 90%, 85%, 80%, 75%, 70%, or less than 70% of the thickness of the sidewall along the proximal portion of the distal section 34. In some embodiments, the length of the distal tapered portion of the distal section 34 may be between about 25 cm and about 35 cm, between about 25 cm and about 30 cm, between about 30 cm and 35 cm, or approximately 30 cm.
In some embodiments, the proximal segment 33 may have an inner diameter of at least about 0.07 inches, 0.075 inches, 0.08 inches, 0.085 inches, 0.09 inches, 0.1 inches, 0.105 inches, or more than 0.105 inches. The proximal segment 33 may have an outer diameter of at least about 0.08 inches, 0.085 inches, 0.09 inches, 0.095 inches, 0.01 inches, 0.105 inches, 0.11 inches, 0.0115 inches, 0.012 inches, or more than 0.012 inches. For example, the inner diameter may be approximately 0.088 inches and the outer diameter may be approximately 0.106 inches. The sidewall of the proximal segment 33 may have a thickness of at least about 0.005 inches, 0.01 inches, 0.015 inches, 0.02 inches, 0.025 inches, or more than 0.25 inches. In some embodiments, the proximal segment 33 has a constant inner and/or outer diameter along its length. In some embodiments, the proximal segment 33 may slightly taper or decrease in diameter along the distal direction. For example, in some embodiments, the outer diameter of the proximal segment 33 may be about 0.106 inches at the distal end and about 0.108 inches at the proximal end.
The length of the proximal segment 33 may be at least about 90 cm, 95 cm, 100 cm, 105 cm, 110 cm, 115 cm, 120 cm, 125 cm, 130 cm, 135 cm, or more than 135 cm. For example, in one embodiment the length is approximately 106 cm. In another embodiment, the length is approximately 117 cm. In some neurovascular applications, the distal end of the proximal segment 33 may extend at least to the Horizontal Petrous segment of the vasculature.
In some embodiments, the length of the distal section 34 may be between about 13 cm and about 53 cm, between about 18 cm and about 48 cm, between about 23 cm and about 43 cm, between about 28 cm and about 38 cm, between about 20 cm and 30 cm, or between about 25 cm and 30 cm. The length of the distal section 34 may be less than or equal to about 20 cm, about 25 cm, about 30 cm, about 33 cm, about 35 cm, about 40 cm, about 41 cm, about 45 cm, about 50 cm, about 55 cm, about 60 cm, about 70 cm, or about 80 cm. The length of the distal section 34 may depend on the degree of tapering of the internal diameter of the distal section 34.
The proximal end 36 of distal section 34 is provided with a proximally extending pull wire 42. Pull wire 42 extends proximally throughout the length of the tubular body 16, to control 24 which may be carried by manifold 18. Axial movement of control 24 produces a corresponding axial movement of distal section 34 with respect to proximal section 33 as has been discussed. Alternatively, the proximal end of pull wire 42 may exit through a port on manifold 18, such that it may be manually grasped and pulled or pushed by the clinician to extend or retract the distal section 34. The length of the pull wire 42 may be between about 700 mm and about 1556 mm, between about 800 mm and about 1456 mm, between about 850 mm and about 1406 mm, between about 900 mm and about 1356 mm, between about 950 mm and about 1306 mm, between about 1000 mm and about 1256 mm, between about 1020 mm and about 1236 mm, between about 1040 mm and about 1216 mm, between about 1060 mm and about 1196 mm, between about 1080 mm and about 1176 mm, between about 1100 mm and about 1156 mm, between about 1110 mm and about 1146 mm, or between about 1120 mm and about 1136 mm. In some preferred embodiments, the length of the pull wire 42 may be between approximately 110-120 cm.
Upon distal advance of pull wire 42 to its limit of travel, an overlap 44 remains between the proximal end 36 of distal section 34 and the proximal section 33. This overlap 44 is configured to provide a seal to enable efficient transmission of vacuum from proximal section 33 to distal section 34. In some embodiments, the length of the pull wire 42 may be limited to ensure that there is a minimal overlap 44 between the proximal segment 33 and the distal segment 34 when the pull wire 42 is fully inserted into the proximal segment 33 or attached manifold in a distal direction. In some embodiments, the length of the proximal segment 33 may be sufficiently long for neurovascular applications such that when the proximal segment is positioned in a relatively proximal position (e.g., the horizontal petrous segment), the neuroanatomy effectively limits the distance by which the distal segment 34 may be extended, ensuring a sufficient overlap 44. For example, the distal segment 34 may not be able to extend further than the M2 segment of the middle cerebral artery (MCA) given its dimensions. Overlap 44 may be provided with any of a variety of additional features to facilitate a seal, such as a gasket, coating or tightly toleranced sliding fit, as described elsewhere herein. In some embodiments, the proximal end of the distal segment 34 may be slightly expanded to create a seal. For instance, the outer diameter of the proximal end of the distal segment 34 and the inner diameter of the proximal segment 33 may both be about 0.088 inches. Preferably the clearance between the OD of the distal section 34 and ID of the proximal section 33, at least in the vicinity of transition 32, will be no more than about 0.005 inches and preferably no more than about 0.003 inches to provide an effective seal in a blood environment. A larger clearance may be more feasible in embodiments comprising a sealing feature as described elsewhere herein.
Following positioning of the distal end of proximal section 33 within the vasculature, such as within the cervical carotid artery, the control 24 is manipulated to distally advance distal section 34 deeper into the vasculature. For this purpose, the pull wire 42 will be provided with sufficient column strength to enable distal advance of the distal tip 38 as will be discussed below.
The pull wire 42 and distal section 34 may be integrated into a catheter as illustrated in
Referring to
In some embodiments, the central lumen 45 may terminate proximal to the opening of the lumen 40. In some embodiments, the central lumen 45 may terminate distal to the opening of the lumen 40 and/or the proximal end of the distal section 34 (e.g., at a point within the lumen 40). For example, the central lumen 45 may terminate at the distal end of the distal section or just short of the distal end (e.g., no more than approximately 1 cm from the distal end). In some implementations, the portion of the pull wire 42, with or without a central lumen 45, which extends beyond the proximal end of the distal section 34 (e.g., into lumen 40) may decrease in stiffness (durometer) in a distal direction. The pull wire 42 may be relatively stiff along the portion proximal to the proximal end of the distal section 34 in order to provide sufficient pushability of the extension catheter. The stiffness of the portion of the pull wire 42 distal of the proximal end of the distal section 34 may substantially match or be less than the stiffness of the distal section 34 along the length of the distal section 34. The portion of the pull wire 42 distal of the proximal end of the distal section 34 may have a uniform stiffness less than the stiffness of the portion proximal of the proximal end of the distal section 34 or it may have a gradated or gradually decreasing stiffness in the distal direction, decreasing from the stiffness of the portion proximal of the proximal end of the distal section 34. For example, the pull wire 42 may comprise metal along the portion proximal to the proximal end of the distal section 34 and may comprise a polymer, softer than the metal, along the portion distal to the proximal end of the distal section 34. The portion distal to the proximal end, in some embodiments, may be extruded with decreasing stiffness in the distal direction.
Disclosed herein are various embodiments for sealing an annular gap between an inner device 3402, such as a tube or catheter, and an outer device 3404, such as a tube or catheter. The inner device 3402 may be the axially translatable distal section 34 of the tubular body 16 of catheter 10 and the outer device 3404 may be the fixed proximal section 33 of the tubular body 16 of catheter 10. The inner device 3402 and the outer device 3404 may form a sealed extendable catheter device 3400. The device 3400 may be sealed within an area of overlap, such as the overlap 44 between the proximal section 33 and the distal section 34 by a sealing feature or mechanism 3406. See
Providing a sealing feature 3406 between the proximal section 33 and the distal section 34 may advantageously provide a seal, and eliminate or reduce the volume of space and/or surface area of device that can act as a stagnation zone for blood that is drawn into the annular gap, which may help reduce or mitigate thrombogenesis. See
In some embodiments, the sealing feature 3406 may be a protrusion 3408 extending from either the outer surface of the inner device 3402 (e.g., an expanded diameter section) or the inner surface of the outer device 3404 (e.g., a reduced diameter section). The protrusion 3408 may form a ring or ring-like annular feature around the outer surface of the inner device 3402 or the inner surface of the outer device 3404. As used herein, “annular” merely requires that the sealing feature extend all the way or substantially all the way around the inner device, sufficient to achieve the sealing function. However it does not require that the seal reside within a single transverse plane as shown in
The protrusion 3408 may operate by forming a close or slight interference sliding fit with the opposing device (the outer diameter of the inner device 3402 or the inner diameter of the outer device 3404).
As shown in
In some embodiments, the protrusion 3408 may prevent the flushing solution from flowing distally beyond the protrusion 3408 (distal or antegrade flow). In some embodiments, the protrusion 3408 may act as a one-way valve allowing distal flow but not fluid flow proximally past the protrusion 3408 (proximal or retrograde flow). The protrusion 3408 may be shaped or otherwise constructed to more easily bend in a distal direction than in a proximal direction to achieve a one-way valve effect. In some embodiments, the protrusion 3408 may be configured to allow distal fluid flow only upon surpassing a threshold fluid pressure. A flushing fluid could be continually maintained proximal the protrusion 3408 and forced to flow past the protrusion 3408 on demand by increasing the fluid pressure, such as with a syringe or other control at a proximal end of the device 3400. The flushing fluid may be provided through a separate tube or lumen which is configured to extend into the annular gap.
The flushing fluid may be provided at times when aspiration is not provided through the catheter 10 or the flushing fluid may be provided contemporaneously with aspiration. The flushing fluid may flush the portion of the gap proximal to the protrusion 3408 and be aspirated via the aspiration provided through the catheter 10. In some implementations, the pressure of the flushing fluid may be sufficient to overpower the suction pressure, at least transiently, and force the one-way fluid seal open to distal flow to flush the portion of the annular gap distal to the protrusion 3408. In some embodiments, flushing fluid may be provided through the entire catheter 10 so as to flush through the inner device 3402, the outer device 3404, and the annular gap between the inner device and outer device, at times when aspiration is not provided through the catheter.
The protrusion 3408 may be the same material or a different material as the portion of the device (e.g., tubular body 16) from which it extends. In some embodiments, the protrusion 3408 may comprise polyether block amide (e.g., PEBAX®), polyethylene, polyurethane, Tecothane®, nylon, etc. In some embodiments, the protrusion 3408 may be formed from a softer material than the inner device 3402, or at least an outer layer (e.g., an outer jacket) of the inner device 3402. In some embodiments, the protrusion 3408 may be formed from a softer material than the outer device 3404 or at least an inner layer (e.g., an inner liner) of the outer device 3404. For example, the protrusion 3408 may be formed as part of an outer jacket of the inner device 3402. In some embodiments, the protrusion 3408 may be coextruded with the outer jacket.
In some embodiments, the protrusion may be adhered to the outer jacket, such as with a biocompatible adhesive, melted onto the outer jacket, molded onto the outer jacket, or otherwise adhered to the outer diameter of the inner device 3402. In some embodiments, the protrusion 3408 may be formed by a discrete tubular segment of the outer jacket having a larger outer diameter than two adjacent segments of the outer jacket which the protrusion 3408 is positioned between. In some embodiments, the protrusion 3408 may be formed as an expanded diameter portion of a tubular segment of the outer jacket. In some embodiments, the protrusion 3408 may be solid throughout. In some embodiments, the protrusion 3408 may be at least partially hollow, which may increase the flexibility of the protrusion 3408.
The protrusion 3408 may have a cross-section along its circumferential axis (around the outer diameter of the outer device 3404) of any suitable shape. For example, the cross-section may be rectangular, square, rounded, triangular, etc. The cross-section may be symmetric or asymmetric about a proximal-to-distal midline. The protrusion 3408 may comprise a proximal surface and a distal surface. In some embodiments, the distal surface may be convex, concave, and/or substantially flat. In some embodiments, the proximal surface may be convex, concave, and/or substantially flat.
The proximal surface and distal surface may have different degrees of stiffness or flexibility. For example, the proximal surface may more easily bend to produce a one-way valve effect as described elsewhere herein. The protrusion 3408 may be shaped with a hinge feature (e.g., a divot in the distal surface) that allows fluid flow in the distal direction but not the proximal direction. Thinner portions of the cross section may be more flexible than thicker portions of the cross-section. In some embodiments, the cross-section may thin-out towards the outer diameter of the protrusion 3408 to facilitate bending of the protrusion 3408 near the point of contact with the outer device 3404 and axial translation of the sealing protrusion 3408 along the inner surface of the outer device 3404.
In some embodiments, the protrusion 3408 or other sealing feature 3406, as described elsewhere herein, may be positioned on an inner surface of the outer device 3404. The protrusion 3408 may be fabricated in the same or similar manner (e.g., from the inner liner of the outer device 3404). In some embodiments, both the inner device 3402 and the outer device 3402 may comprise protrusions 3408 or other sealing feature 3406. A protrusion 3408 on the outer device 3404 may be positioned to be proximal to, distal to, or axially aligned with a protrusion 3408 on the inner device 3402 when the extendable device 3400 is in a fully extended position or when the extendable device 3400 is in a fully retracted position. A protrusion 3408 on the inner device 3402 may be configured to axially cross over a protrusion 3408 on the outer device 3404 as the inner device 3402 is axially translated relative to the fixed outer device 3404, or the inner device 3402 and outer device 3404 may be configured such that the protrusions 3408 remain in their respective proximal/distal spatial relationships. In some embodiments, protrusions 3408 on the inner device 3402 and the outer device 3404 may be configured to serve as stops that abut one another and limit axial translation of the inner device 3402 with respect to the outer device 3404 in a distal and/or proximal direction.
The inner device 3402 may contain one or more protrusions 3408 (e.g., 1, 2, 3, 4, 5, etc.) and/or the outer device 3404 may contain one or more protrusions 3408 (e.g., 1, 2, 3, 4, 5, etc.).
In some embodiments, one or more protrusions 3408 on the inner device 3402 may be configured to extend distally beyond the distal end of the outer device 3404, such as in a fully extended configuration. In some embodiments, one or more protrusions 3408 on the inner device 3402 may be configured not to extend distally beyond the distal end of the outer device 3404 such that they remain within the annular gap, such as in a fully extended configuration. In some embodiments, one or more protrusions 3408 on the outer device 3404 may be configured to extend proximally beyond the proximal end of the inner device 3402, such as in a fully extended configuration. In some embodiments, one or more protrusions 3408 on the outer device 3404 may be configured not to extend proximally beyond the proximal end of the inner device 3402, such as in a fully extended configuration.
In some embodiments, the protrusion 3408 may be uniformly distributed around the circumference of the inner device 3402 or outer device 3404 at a given axial position along the length of the inner device 3402 or outer device 3404, forming a simple ring defining a transverse plane that is 90° from the longitudinal axis of the catheter. In other embodiments, the protrusion 3408 may incline in an axial direction as it circumnavigates the outer circumference of the inner device 3402 or the inner circumference of the outer device 3404. For example, the protrusion 3408 may shaped as an annular circle (90° to the longitudinal axis), oval (inclined at an angle other than 90°), diamond, or other suitable shape that is slanted along the axial direction such that the protrusion 3408 forms a proximal tip 3408a and/or a distal tip 3408b.
In some embodiments, the slanted protrusion may form a pointed tip as shown in
Protrusions 3408 may comprise any combination of the views and shapes depicted as well as other shapes. For example, in some embodiments, the protrusion 3408 may comprise a rounded proximal tip 3408a and a pointed distal tip 3408b or vice versa. In some embodiments, the protrusion may comprise a proximal tip 3408a but no defined distal tip 3408b (e.g., the protrusion is distributed evenly around at least a portion of the circumference at its distal end) or vice versa. The configuration of the slanted protrusions 3408, particularly the chevron-shaped profiles, may reduce the force required to axially translate the inner device 3402 relative to the outer device 3404, while maintaining a sealed space.
As shown in
For instance, in some embodiments, the width 3407a near the proximal point 3408a and/or the distal point 3408b may be between approximately 0.05 and 0.3 inches, 0.1 and 0.2 inches, or 0.11 and 0.13 inches. The width 3407a may vary in a continuous pattern across the circumference of the inner device 3402.
In some embodiments, the angle θ may be defined via a straight line connecting the proximal tip 3408a to a point 3452 on the proximal edge opposite the distal tip 3408b or connecting the distal tip 3408b to a point 3452 on the distal edge opposite the proximal tip 3408a, which in the illustrated embodiment lies on a proximal edge 3409 of the inclined seal. In some embodiments, the angle θ may be defined by a best fit straight line along the proximal and/or distal edge of the protrusion, in the case of nonlinear edges. The other examples of protrusions 3408 disclosed herein may have the same or similar dimensions.
In some embodiments, the trailing and/or leading edge of the protrusion 3408 may form an angle θ relative to the longitudinal axis that is no larger than about 10 degrees, 15 degrees, 20 degrees, 25 degrees, 30 degrees, 35 degrees, 40 degrees, 45 degrees, 50 degrees, 55 degrees, or 60 degrees. In some embodiments, the angle θ may be between about 15 and 45 degrees, 20 and 40 degrees, 20 and 30 degrees, or 30 and 40 degrees. Protrusions 3408 having a lower angle θ may facilitate sliding of the inner device 3402 within the outer device 3404 in an axial direction.
The illustrated protrusion 3408 is in the form of an inclined annular seal having a distal edge 3450 on the opposite axial end of the seal from proximal edge 3409. The distal edge 3450 may reside on a plane that is substantially parallel to the proximal edge 3409 in an embodiment having a constant thickness 3407a, both of which are non perpendicular to the longitudinal axis of the catheter.
The inclined distal edge 3450 has a first, distal transition or limit at leading point 3408b and a second, proximal limit 3452 which is axially proximally offset from the first distal limit by at least about 2 mm; at least about 3 mm or 4 mm or more.
The inclined proximal edge 3409 extends between a distal limit 3454 and a proximal limit 3408a. As a result of the axial offset and width 3407a of the protrusion 3408, a window 3456 may be formed between the distal limit 3454 and proximal limit 3452 of the opposing edges of the seal depending upon the incline angle of the seal. See
The window 3456 may have a major axis within the range of from about negative 0.5 mm (slight axial overlap of the distal sliding surface 3458 and proximal sliding surface 3460) to about 4 mm, and in some implementations at least about 1 mm or 2 mm and in some cases within the range of from about 2 mm to about 3 mm. The major axis of the window 3456 is about 2.6 mm in one implementation having a seal width 3407a of about 2 mm and a catheter OD of about 0.086 inches.
An end view of the distal edge 3450 and or proximal edge 3409 taken along a viewing axis that is perpendicular to the plane of the respective edge can define an ellipse. In one implementation, the ellipse dimensions are 0.086″ in the minor axis direction, which is equal to the OD of the catheter. The ellipse is about 0.2057″ in the major axis direction, about 2 to 2.5 times the catheter diameter. This means the seal inclines at about 30 degrees to the long axis of the catheter. At an incline of about 15 degrees the long axis increases to almost 4 times the catheter diameter. This is rather steep and may be a reasonable limit. At the other extreme a 75 degree angled seal (almost straight across) would not have sufficient axial offset of the opposing sliding surfaces, (desirable to minimize drag) if the seal width was 25% or less of the catheter diameter. This would be an ellipse ratio of only about 1.03. As the seal gets wider, the minimum ratio would climb with the angle dropping off. Thus, ellipse major axis dimensions within the range of from about 1.25 to about 4 times the minor axis dimension will typically be used, often within the range of from about 1.5 to about 3×× the minor axis dimension.
Preferably, the trailing edge 3454 (inside the ellipse) of the seal on one side should overlap minimally, or ideally not at all with the leading edge 3452 (inside of the ellipse) of the seal on the opposite side.
As a consequence of the angled nature of the annular seal, the overall length in the catheter axial direction from distal tip 3408b to proximal tip 3408a will often be at least about 1.5 times or two times the width 3407a. In some implementations, the overall tip to tip length may be at least about 2.5 times or 3 times the width 3407a. Multiples within the range of from about 1.5 times and about 5 times, or from about 2 times and about 3.5 times may be utilized depending upon desired performance. In one implementation having a width 3407a of about 2 mm and a catheter OD of about 0.086 inches, the overall axial length from tip to tip is between about 4 mm and about 8 mm, between about 6 mm and about 7 mm and optionally about 6.7 mm.
The overall length may be elongated further by introducing an axial extension segment on each side of the catheter such as at about the midpoint between proximal tip 3408a and distal tip 3408b. In this implementation the distal edge 3450 for example would not appear as it does in side elevational view (
The chevron configured seal allows for effective sealing inside another tube by not requiring the other (outer) tube to have a friction fit around a full 360 degrees at the same axial location transverse plane. The contact points of the chevron allow the inner and outer tubes to be inclined slightly to each other to relieve the friction of the sealing surface and at the midpoint of the chevron the outer tube can ovalize slightly while never allowing a leak path to form.
The protrusions 3408 disclosed herein may be any suitable thickness. For example, the protrusions 3408 may be no greater than approximately 0.01 mm, 0.025 mm, 0.05 mm, 0.075 mm, 0.1 mm, 0.25 mm, 0.5 mm, 0.75 mm, 1 mm, 2 mm, 3 mm, 4 mm, 5 mm, less than 0.1 mm, more than 5 mm, or a thickness within a range defined there between. In some embodiments, the protrusions 3408 may have uniform thickness. In some embodiments, the thickness may be between about 0.001 and 0.005 inches, 0.0015 and 0.004 inches, or 0.002 and 0.003 inches. In some embodiments, the protrusions 3408 may have variable thickness as they extend circumferentially around the circumference of the inner device 3402 or outer device 3404. As described elsewhere herein, the protrusion 3408 may have an outer diameter that is substantially equal to the inner diameter of the outer device 3404. For example, both diameters may be between about 0.085 and 0.09 inches, 0.086 and 0.089 inches, or 0.087 and 0.088 inches. In some implementations, the outer diameter of the protrusion 3408 and the inner diameter of the outer device 3404 may vary by less than about 0.002 inches, 0.001 inches, or 0.005 inches.
In some embodiments, the protrusion 3408 may be formed from the same material as an outer layer of the inner device 3402, such as Pebax®. The protrusion may be formed by extruding the material in a similar way one or more layers of the inner device 3402 are formed. The extruded material may be cut (e.g., diagonally cut) to form the shape of the ring having dimensions 3407a and 3408b. In some embodiments, the protrusion 3408 may be positioned around the inner device 3402 and then heated to laminate the protrusion 3408 to the outer surface of the inner device 3402, such as in a hot box. In some embodiments, the protrusion 3408 may be adhered to the inner device 3402 using an adhesive, such as a biocompatible adhesive. In some implementations, the protrusion may be post-processed. For example, the protrusion may be shaped by heating in a mold. The mold may be a glass mold. The mold may have an inner diameter approximately equal to the inner diameter of the outer device 3404 or slightly larger. For example, the mold may have an inner diameter of about 0.088 inches to achieve a protrusion 3408 having a diameter of approximately 0.0874 inches.
In some implementations, the protrusion 3408 may be molded or otherwise processed prior to attachment of the protrusion 3408 to the inner device 3408. In some embodiments, the protrusion 3408 may be attached or formed near the proximal end of the inner device 3402 as described elsewhere herein. For example, the protrusion 3408 may be formed within 5 cm, 4 cm, 3 cm, or 2 cm from the proximal end of the inner tubular body 3402. In some embodiments, as described elsewhere herein, the protrusion 3408 may be attached or formed on the most proximal Pebax® segment (e.g. a 72D segment). The protrusion 3408 may be attached or formed distally to any proximal Vestamid® segments. When attached or formed near the proximal end of the inner device 3402, the protrusion may have a durometer that is the same or less than that of the inner device 3402 at the same location. For example, the protrusion 3408 may have a durometer between about 45D and 70D, 50D and 65D, or 55D and 60D. For instance, a 55D protrusion 3408 may be positioned around a 72D segment of the outer jacket of the inner device 3402.
In some embodiments, the protrusion 3408 may be a spiral that extends along an axial length of the inner device 3402 and/or the outer device 3404. In some embodiments, the spiral may terminate at either its distal end and/or proximal end in closed circumference rings or connect to closed circumference rings. In some embodiments, the spiral may terminate at its distal end and/or proximal end in an open configuration which may allow some blood to pass through a helical passage formed by the spiral. The spiral may nonetheless impede the flow of blood into the annular gap. In some implementations, the smaller the pitch of the spiral the larger the impediment the spiral may provide against blood ingress. Rotation of the inner device 3402 in a first direction, depending on the direction (e.g., right handed or left-handed) of the spiral, may cause the spiral to expel fluid in a distal direction while rotation in a second direction may draw in blood. Rotation in the first direction may be used to expel a flushing solution as described elsewhere herein.
In some embodiments, the sealing feature 3406 may be an active feature which expands or otherwise activates to seal the annular gap and/or which can be deactivated to allow flow through the annular gap. The sealing feature 3406 may be deactivated when the inner device 3402 and the outer device 3404 are axially translated relative to one another so as to allow easier movement (e.g., less friction). The sealing feature 3406 may be activated when the inner device 3402 and the outer device 3404 are being used in a fixed position, such as a fully retracted and/or fully extended position.
Referring to
The expandable bulge 3410 may be coupled to the inner device 3410 in a manner that allows axial compression of the expandable bulge 3410 along the outer surface of the inner device 3402. In some embodiments, the outer diameter of the expandable bulge 3410 in an un-activated or un-expanded state may extend beyond the outer diameter of the inner device 3402 but may not extend to the inner diameter of the outer device 3404 such that it does entirely seal the annular gap. In other embodiments, the expandable bulge 3410 may be applied over a smooth portion of the outer circumference of the inner device 3402. The expandable bulge 3410 may be fixed, such as at a proximal end, to the inner device 3402.
As shown in
Providing a distally directed counterforce on the inner device 3402 such as by pushing on the inner device 3402 (e.g., pushing on the spine 3403 through which the tension cable 3411 extends) may facilitate expanding the expandable bulge 3410 without axially translating the inner device 3402 relative to the outer device 3402, such as pulling the inner device 3410 proximally along with the tension cable 3411. In other embodiments, the expandable bulge 3410 may be compressed by pushing on a push wire which may be connected to a proximal end of the expandable bulge 3410. The expandable bulge 3410 may be fixed to the inner device 3410 at a distal end of the expandable bulge 3402. The expandable bulge 3402 may be positioned at a distal end or intermediate portion of the inner device 3402.
In some embodiments, the expandable bulge 3410 may be expandable by non-mechanical means. For example, the expandable bulge 3410 may comprise a light-sensitive or electrosensitive material, such as a light-sensitive hydrogel and/or an electrosensitive hydrogel. An electric current or light may be passed through the lumen, which may serve as or may comprise an insulator or fiber optic cable. The hydrogel may expand upon the application of light and/or an electric current and may collapse upon removal of the stimuli or vice-versa. In some embodiments, the expandable bulge 3410 may be inflatable and the lumen may serve as a passage for providing pressurized fluid (e.g. a gas or liquid, such as saline) which serves to inflate the expandable bulge 3410. The expandable bulge 3410 may be inflated and deflated to a controllable extent by controlling the pressure applied to the inflating fluid.
In some embodiments, the sealing feature 3406 may comprise a flange 3412.
In some embodiments, the flange 3412 may be formed integrally with the outer device 3404. For example, the flange 3412 may be extruded as a part of an inner liner and/or a part of an outer jacket of the outer device 3412. In some embodiments, the flange 3412 may be the same material as a layer of the outer device 3412 but may be formed relatively thinner so that it is more flexible. In some embodiments, the flange 3412 may be formed as a separate component which is coupled to the outer device 3404. For example, the flange 3412 may be adhered to the outer device 3404 or melted or molded onto the outer device 3404. The flange may be a distal segment of an outer jacket of the outer device 3404. The flange 3412 may be relatively compliant. The flange 3412 may be configured to extend, in an unbiased configuration, radially inward in a substantially normal relation to the inner surface of the outer device 3404. The flange 3412 may be configured to extend, in an unbiased configuration, radially inward and somewhat in a distal direction such that it forms an oblique angle with the inner surface of the outer device 304.
The flange 3412 may comprise an inner diameter in an unbiased configuration which is smaller than the outer diameter of the inner device 3402. In some embodiments, the flange 3412 may be thicker along or near its outer diameter than along or near its inner diameter. In some embodiments, the flange 3412 may comprise uniform thickness. Extending the inner device 3402 past the distal end of the outer device 3404 may cause the flange 3412 to bend in a distal direction such that the inner diameter of the flange 3412 expands to accommodate the inner device 3404 and form a fluid seal along the outer surface of the inner device 3402 as shown in
In some embodiments, the flange 3414 may maintain a flushing fluid proximal to the flange 3414 and/or may act as a one-way valve in the same manner as described with various configurations of the protrusion 3408 described elsewhere herein. Providing a flange 3414 or other sealing feature 3406 at a distal end of the outer device 3404 may advantageously maximize the volume of the annular gap which is sealed from the physiological environment. In some embodiments, the inner device 3402 may comprise a flange 3412 extending from its outer diameter in a radially outward direction, which may comprise features similar to the flange 3412 extending from the outer device 3402. For example, the outer diameter of the flange 3412 may be larger than the inner diameter of the outer device 3404. The flange 3412 may be positioned at a proximal end of the inner device 3402.
In some embodiments, the sealing feature 3406 may comprise an expanded diameter portion of the inner device 3402, such as a hub 3414.
In some embodiments, the hub 3414 may comprise the same material as an outer jacket of the inner device 3404 or as any other layer of the inner device 3402. In some embodiments, the hub 3414 may be relatively softer and/or more flexible than the remaining length of the inner device 3402. In some embodiments, the hub 3414 may be relatively harder and/or stiffer than the remaining length of the inner device 3402. In some embodiments, the hub 3414 may comprise a uniform material extending between the non-expanded outer diameter of the inner device 3402 and the inner diameter of the outer device 3404. In some embodiments, the hub 3414 may comprise multiple layers between the non-expanded outer diameter of the inner device 3402 and the inner diameter of the outer device 3404. The layers may be of the same or different materials. In some embodiments, one or more outer layers may be softer, more flexible, and/or more lubricious than one or more inner layers. The outer layer or layers may facilitate smooth interaction with the outer device 3404 and the inner layers may provide structural support to the outer layers. In some embodiments, the hub 3414 may be positioned adjacent to a radiopaque ring as illustrated in
In some embodiments, the inner device 3404 may comprise a spine 3403 (e.g., a hypotube spine) as described elsewhere herein. The spine 3403 may comprise a lumen 3401. The spine 3403 may be positioned along an outer-most diameter of the inner device 3402. The spine 3403 may merge with the hub 3414 as shown in
The hub 3414 may thereby comprise a distal port 3454 on a lumen extending through the seal which allows delivery of flushing fluid through the lumen 3401 across the seal and into the annular gap. Providing pressure from the proximal end of the lumen 3401 may allow delivery of flushing fluid while preventing proximal fluid flow through the port of the sealing feature 3406. In some embodiments, the lumen 3401 may extend linearly through the hub 3414 such that the port 3454 is collinear with the remainder of the lumen 3401. In some embodiments, the lumen may turn, such as in a circumferential direction, and/or branch off into multiple ports. Multiple ports may be positioned, for example, at different circumferential points around the hub 3414.
In some embodiments, the sealing feature 3406 may be dynamically responsive to movements of the inner device 3402 and/or outer device 3404. For example, the sealing feature 3406 may comprise spring devices which expand in an unbiased state and contract under force provided by movement of the inner device 3402, for example, and a counter frictional force between the inner device 3402 and the outer device 3404.
As shown in
The inner annulus 3418a may be configured to form a sliding interference fit with the outer diameter of the inner device 3402. The outer annulus 3418b may be configured to form a sliding interference fit with the inner diameter of the outer device 3404. The inner annulus 3418a may have a first coefficient of friction with respect to the inner device 3402 and the outer annulus 3418b may have a second coefficient of friction with respect to the outer device 3404. The first and second coefficients of friction may be the same or one may be larger than the other. Although the outer annulus 3418 is shown as comprising a complete circumference in
The spring sealing feature 3416 may comprise one or more radially compressible support structures such as springs 3422 extending from around the circumference of the inner annulus 3418a of the proximal sliding ring 3418 to the inner annulus 3418a of the distal sliding ring 3418. For instance, the springs 3422 may comprise a plurality of spring struts extending parallel to a longitudinal axis of the device 3400 from one sliding ring 3418 to another. The spring 3422 may comprise a coil spring wrapping helically around the inner device 3402. The spring 3422 may comprise a spring mesh. The spring 3422 may be convex around the inner device 3402 or configured to bulge radially outward, within at least one portion positioned intermediately between the proximal end and distal end of the spring 3422, when in an unbiased or relaxed state, as shown in
The spring or springs 3422 may be covered or coated with an elastic membrane or film (not shown) which covers an outer and/or inner surface of the springs 3422 such that a fluid barrier is formed by the membrane circumferentially around the inner device 3402, the fluid barrier extending from the proximal sliding ring 3418 to the distal sliding ring 3418. In an unbiased configuration, the spring 3422 and the elastic membrane are compressed against an inner surface of the outer device 3404, as depicted in
Under tension, the spring 3422 may stretch in the axial direction thereby reducing its outer diameter. The outer diameter of the spring 3422 may be reduced such that the spring 3422 and/or elastic membrane no longer contacts the inner surface of the outer device 3404, at least along a portion of the circumference, and allows fluid flow across the spring sealing feature 3416. Fluid may flow between the spokes 3418c of the proximal and distal sliding rings 3418 to flow across the surface of the fluid barrier formed around the inner device 3402. Removing contact between the membrane-encompassed spring 3422 and the inner surface of the outer device 3402 may reduce overall friction and facilitate axial translation of the inner device 3402 relative to the outer device 3404. In some embodiments, the axial extension of the spring 3422 may reduce the compressive force of the spring sealing feature 3416 against the outer device 3404 but still maintain the spring sealing feature 3416 in contact with the outer device 3404. Reducing the compressive force may reduce friction and facilitate translation of the inner device 3402 with respect to the outer device 3404 while maintaining, at least to a degree, a fluid seal.
When the proximal force on the inner device 3402 is removed, the tension may be removed from the spring 3422 and the spring 3422 may contract bringing the proximal and distal rings 3418 closer together. The spring 3422 may expand to the inner surface of the outer device 3404 sealing device 3400, blocking fluid flow across the spring sealing feature 3416. The spring 3422 may be designed with a spring constant, such that it requires less force to deform the spring 3422 than to overcome the friction resisting sliding between the outer annulus 3418b and the inner surface of the outer device 3404. The spring 3422 may be configured to extend before the lagging sliding ring 3418 begins to translate, following the leading sliding ring 3418.
In some embodiments, the spring sealing feature 3416 may use two ridge features 3420, one positioned on a distal side of the distal sliding ring 3418 and one positioned on the proximal side of the proximal sliding ring 3418, in addition to or alternatively to the intermediate ridge feature 3420. Providing a transient seal that only allows fluid flow during axial translation of the inner device may significantly reduce exposure of the annular gap to proximal blood flow. Providing a transient seal that reduces friction upon axial translation of the inner device 3402 may improve the ability to readily translate the inner device 3402 while generally maintaining a fluid seal. The same tradeoff between friction that seals the annular gap and friction that inhibits smooth axial translation is not necessarily required with a dynamic seal.
Other various configurations of the sealing feature 3406 may be dynamically responsive to movements of the inner device 3402.
As shown in
The inner device 3402 may comprise one or more key features 3432 as illustrated in
A torsion spring 3434 may extend between the large diameter ring 3428 and the small diameter ring 3430. The torsion spring 3434 may have a convex configuration around the inner device 3402 such that it extends radially outward between the large diameter ring 3428 and the small diameter ring 3430 so as to compress against the inner surface of the outer device 3404. The spring sealing device 3426 may comprise an elastic membrane or film coupled to the torsion spring 3434 to form a fluid barrier circumferentially surrounding the inner device 3402 as described elsewhere herein.
Rotation of the small diameter ring 3430 in a first direction (e.g., clockwise or counter clockwise) may cause the torsion spring 3434 to collapse such that the elastic membrane is no longer pressed into contact with the outer device 3404. The elastic membrane may form a fluid seal around the circumference of the inner surface of the outer device 3404 when compressed against the outer device 3404, similar to the spring sealing feature shown in
Rotation of the inner device 3404 may thereby allow fluid flow across the spring sealing device 3426. The inner device 3404 may be rotated and maintained in a rotated position to allow axial translation of the inner device 3402 with respect to the outer device 3404 in order to reduce the friction between the inner device 3402 and outer device 3404. The large diameter ring 3428 may be fixed to the outer device 3404 near a distal end of the outer device 3404, maximizing the length of the annular gap that is sealed from blood exposure.
In some embodiments, the small diameter ring 3430 may be fixed to the inner device 3402 such that it is not axially translatable with respect to the inner device 3402. The small diameter ring 3430 may be an annular projection extending from the inner device 3402. The small diameter ring 3430 may be integral with the inner device 3402. The large diameter ring 3428 may be axially translatable (e.g., slidable) with respect to the inner surface of the outer device 3404. The large diameter ring 3428 may resist or prohibit rotation with respect to the inner surface of the outer device 3404. The spring constant of the torsion spring 3434 may be configured such that less torque is required to collapse the spring than to rotate the large diameter ring 3428 with respect to the outer device 3404. The large diameter ring may provide a counter force that allows the torsion spring 3434 to collapse.
In some embodiments, the large diameter ring 3428 may be mechanically prevented from rotating with respect to the outer device 3404. For example, the large diameter ring may comprise key features and the inner surface of the outer device 3404 may comprises corresponding recesses or grooves, as described elsewhere herein or vice versa. In some embodiments, the torsion spring 3434 and/or the elastic membrane may extend from the small diameter ring to an outer annulus of the large diameter ring 3428 or some circumference between an inner diameter and outer diameter of the large diameter ring 3428. Rotation of the inner device 3402 may collapse the torsion spring 3434 to allow fluid flow and/or reduce friction between the inner device 3402 and outer device 3404 as described with respect to
Disclosed herein are various embodiments for sealing an annular gap between vascular device such as device 3400, described elsewhere herein, and a body vessel such as a blood vessel (e.g., a neurovascular artery). Sealing a blood vessel around a catheter device, particularly a catheter configured for the removal (e.g., aspiration) of a blood clot may advantageously prevent blood flow from carrying a clot or fragment of a clot, such as a clot captured on a distal end of the catheter, further downstream. For example, for a device positioned upstream of the clot, such as in a neurovascular artery, the seal between the device and the blood vessel may prevent antegrade blood flow from dislodging a captured blood clot from a distal end of the device and carrying it downstream, which could result in an embolism in a downstream location.
The device 3400 may comprise a vessel sealing feature 3440 positioned on an outer surface of the device 3400 (e.g., on an outer surface of the outer access catheter device 3404).
The vessel sealing feature 3440 may comprise the same or similar features as protrusion 3408 configured to extend around the outer surface of the inner device 3402, except that it is configured to extend around the outer surface of the outer device 3404. The vessel sealing feature 3440 may form an expanded diameter portion of the device 3400 (or at least of a portion of the device inserted into the vasculature to be occluded by the vessel sealing feature 3440). The vessel sealing feature 3440 may be extremely compliant such that it may have a diameter large enough to seal a blood vessel of an unknown or variable diameter while being soft and deformable enough to be compressed and placed contact with the blood vessel wall without damaging (e.g., rupturing or tearing) the blood vessel wall or intima.
The vessel sealing feature 3440 may be formed as a part of an outer jacket as described elsewhere herein. The vessel sealing feature 3440 may comprise a soft elastomeric polymer. The vessel sealing feature 3440 may be formed from a same or different material as the device 3400 (e.g., the outer jacket of the device). The vessel sealing feature 3440 may be a separate component which is coupled to the device 3400. For example, the vessel sealing feature 3440 may be a preformed ring, similar to a wide O-ring, which is placed over the outer surface of the device 3400. The device 3400 may be configured with a circumferential recess or groove configured to receive the vessel sealing feature 3440. The vessel sealing feature 3440 may have an inner diameter that is smaller, in an unbiased state, than the outer diameter of the device 3400 (or the recessed diameter of the groove). The vessel sealing feature 3440 may need to be at least partially expanded (e.g., stretched) in order to position the vessel sealing feature 3440 over the device 3400 and the compressive elastic force of the vessel sealing feature 3440 may frictionally secure the vessel sealing feature 3440 to the device 3400.
In some embodiments, the vessel sealing feature 3440 may be additionally or alternatively secured to the device by melting or molding the sealing feature onto the device 3400 or using an adhesive (e.g., a biocompatible adhesive). In some embodiments, the vessel sealing feature 3400 may be softer and more flexible or compliant along an outer diameter than along an inner diameter. In some embodiments, the vessel sealing feature 3400 may be thinner along an outer diameter than along an inner diameter. In some implementations, the vessel sealing feature 3440 may be custom-formed in size and/or shape to the anatomy of a particular vessel. The anatomy may be patient-specific. In some embodiments, the vessel sealing feature 3440 is interchangeable such that a custom or otherwise specifically shaped and/or sized vessel sealing feature 3440 may be replaceably attached to the device 3400. In some embodiments, the vessel sealing feature 3440 may be a soft hydrogel. The hydrogel may be configured to swell nominally or not at all in situ.
In some embodiments, the vessel sealing feature 3440 may be active. The vessel sealing feature 3440 may comprise the same or similar features as the expandable bulge 3410 described elsewhere herein. For example, the vessel sealing feature 3440 may comprise a light-sensitive or electrosensitive material, such as a light-sensitive hydrogel and/or an electrosensitive hydrogel. An electric current or light may be passed through an insulator or fiber optic cable to the hydrogel or other active material. The hydrogel may expand upon the application of light and/or an electric current and may collapse upon removal of the stimuli or vice-versa.
A hydrogel may be configured to swell to a controlled or expected volume when exposed to the physiological environment in situ. For example, the hydrogel may be configured to swell in response to body temperature, blood exposure, and/or interaction with a physiological factor, such as an enzyme. In some implementations, the amount of swelling may be controlled by a parameter of the stimulus (e.g, the amount of current or intensity of the light).
In some embodiments, the vessel sealing feature 3440 may be inflatable via pressurized fluid (e.g. a gas or liquid, such as saline) which serves to inflate the vessel sealing feature 3440 such as an inflatable balloon. The vessel sealing feature 3440 may be inflated and deflated to a controllable extent by controlling the pressure applied to the inflating fluid. In some embodiments, the vessel sealing feature 3440 may be configured to be in-line or flush with the outer diameter of the device 3400 in an inactivated state. In other embodiments, the vessel sealing feature 3440 may extend slightly beyond the outer diameter of the device 3400 in an inactivate state, but not to the extent that it seals the blood vessel or comes into significantly increased contact with the blood vessel creating additional friction.
Any of the catheter shaft or sections of the catheter shaft or telescoping extensions in accordance with the present invention, such as inner device 3402 or outer device 3404, may comprise a multi-layer construct having a high degree of flexibility and sufficient push ability to reach deep into the cerebral vasculature, such as at least as deep as the petrous, cavernous, or cerebral segment of the internal carotid artery (ICA).
In one example, referring to
A braid such as a 75 ppi stainless steel braid 3010 may thereafter be wrapped around the inner liner 3014 through a proximal zone up to a distal transition 3011. From the distal transition 3011 to the distal end of the catheter 3000, a coil 3024 comprising a shape memory material such as a Nitinol alloy may thereafter be wrapped around the inner liner 3014. In one implementation, the Nitinol coil has a transition temperature below body temperature so that the Nitinol resides in the austinite (springy) state at body temperature. Adjacent loops or filars of the coil 3024 may be closely tightly wound in a proximal zone with a distal section having looser spacing between adjacent loops. In an embodiment having a coil section 3024 with an axial length of at least between about 20% and 30% of the overall catheter length, (e.g., 28 cm coil length in a 110 cm catheter shaft 3000), at least the distal 1 or 2 or 3 or 4 cm of the coil will have a spacing that is at least about 130%, and in some implementations at least about 150% or more than the spacing in the proximal coil section. In a 110 cm catheter shaft 3000 having a Nitinol coil the spacing in the proximal coil may be about 0.004 inches and in the distal section may be at least about 0.006 inches or 0.007 inches or more. In embodiments comprising an extension catheter, the distal extendable section of the catheter may be constructed according to the foregoing. The length of the coil 3024 may be proportioned to the length of the extendable catheter segment or the total (e.g., extended) length of the catheter 3000. The coil 3024 may extend from a distal end of the extendable segment over at least about 50%, 60%, 70%, 80%, or 90% of the length of the extendable segment. In some embodiments, the catheter 3000 or the extendable segment may not comprise a braid and the coil 3024 may extend to the proximal end of the extendable segment (100% of the length). [0082] The distal end of the coil 3024 can be spaced proximally from the distal end of the inner liner 3014, for example, to provide room for an annular radiopaque marker 3040. The coil 3024 may be set back proximally from the distal end, in some embodiments, by approximately no more than 1 cm, 2 cm, or 3 cm. In one embodiment, the distal end of the catheter 3000 is provided with a beveled distal surface 3006 residing on a plane having an angle of at least about 10° or 20° and in one embodiment about 30° with respect to a longitudinal axis of the catheter 3000. The radiopaque marker 3040 may reside in a plane that is transverse to the longitudinal axis. Alternatively, at least the distally facing edge of the annular radiopaque marker 3040 may be an ellipse, residing on a plane which is inclined with respect to the longitudinal axis to complement the bevel angle of the distal surface 3006.
After applying the proximal braid 3010, the distal coil 3024 and the RO marker 3040 an outer Jacket 3020 maybe applied such as a shrink wrap tube to enclose the catheter body 3000. The outer shrink-wrapped sleeve 3020 may comprise any of a variety of materials, such as polyethylene, polyurethane, polyether block amide (e.g., PEBAX™), nylon or others known in the art. Sufficient heat is applied to cause the polymer to flow into and embed the proximal braid and distal coil.
In one implementation, the outer shrink wrap jacket 3020 is formed by sequentially advancing a plurality of short tubular segments 3022, 3026, 3028, 3030, 3032, 3034, 3036, 3038 concentrically over the catheter shaft subassembly, and applying heat to shrink the sections on to the catheter 3000 and provide a smooth continuous outer tubular body. The foregoing construction may extend along at least the most distal 10 cm, and preferably at least about the most distal 20 cm, 25 cm, 30 cm, 35 cm, 40 cm, or more than 40 cm of the catheter body 3000. The entire length of the outer shrink wrap jacket 3020 may be formed from tubular segments and the length of the distal tubular segments (e.g., 3022, 3026, 3028, 3030, 3032, 3034, 3036, 3038) may be shorter than the one or more tubular segments forming the proximal portion of the outer shrink wrap jacket 3020 in order to provide steeper transitions in flexibility toward the distal end of the catheter 3000.
The durometer of the outer wall segments may decrease in a distal direction. For example, proximal segments such as 3022 and 3026, may have a durometer of at least about 60 or 70D, with gradual decrease in durometer of successive segments in a distal direction to a durometer of no more than about 35D or 25D or lower. A 25 cm section may have at least about 3 or 5 or 7 or more segments and the catheter 3000 overall may have at least about 6 or 8 or 10 or more distinct flexibility zones. The distal 1 or 2 or 4 or more segments 3036, 3038, may have a smaller OD following shrinking than the more proximal segments 3022-3034 to produce a step down in OD for the finished catheter body 3000. The length of the lower OD section 3004 may be within the range of from about 3 cm to about 15 cm and in some embodiments is within the range of from about 5 cm to about 10 cm such as about 7 or 8 cm, and may be accomplished by providing the distal segments 3036, 3038 with a lower wall thickness.
Referring to
In another embodiment, the most distal portion of the catheter 3000 may comprise a durometer of less than approximately 35D (e.g., 25D) to form a highly flexible distal portion of the catheter and have a length between approximately 25 cm and approximately 35 cm. In other embodiments, the length may be between approximately 15 cm and approximately 25 cm. The distal portion may comprise one or more tubular segments of the same durometer (e.g., segment 3038) or of different durometers. In some embodiments, one or more of the distal most segments may comprise a polyether-based thermoplastic polyurethane (e.g., Tecothane®). More proximal segments may comprise a polyether block amide (e.g., PEBAX®). A series of proximally adjacent tubular segments to the distal portion may form a transition region between a proximal stiffer portion of the catheter 3000 and the distal highly flexible portion of the catheter. The series of tubular segments forming the transition region may have the same or substantially similar lengths, such as approximately 1 cm. The relatively short length of the series of tubular segments may provide a steep drop in durometer over the transition region. For example, the transition region may have a proximal tubular segment 3036 (proximally adjacent the distal portion) having a durometer of approximately 35D. An adjacent proximal segment 3034 may have a durometer of approximately 55D. An adjacent proximal segment 3032 may have a durometer of approximately 63D. An adjacent proximal segment 3030 may have a durometer of approximately 72D. One or more of the segments within the transition region may comprise a length between about 1 and 4 cm. For example, the transition region may comprise a proximal segment 3036 approximately 4 cm and 35D, an adjacent segment 3034 approximately 3 cm and 37D, an adjacent segment 3032 approximately 1 cm and 47D, an adjacent segment 3030 approximately 1 cm and 55D, an adjacent segment 3028 approximately 1 cm and 63D, and an adjacent segment 3026 approximately 1 cm and 72D. In some embodiments, the length of the distal portion of the catheter 3000, including the highly flexible distal portion and the transition region, may be between about 25-30 cm, between about 30-35 cm, between about 35 to 40 cm, or between about 40-45 cm. More proximal segments may comprise a durometer or durometers greater than approximately 72D and may extend to the proximal end of the catheter or extension catheter segment. For instance, an extension catheter segment may comprise a proximal portion greater than approximately 72D between about 1 cm and about 3 cm. In some embodiments, the proximal portion may be about 2 cm long. In some embodiments, the most distal segments (e.g., 3038-3030) or at least the transition region may comprise PEBAX® and more proximal segments may comprise a generally stiffer material, such as Vestamid®.
The inner diameter of the catheter 3000 or catheter extension segment may be between approximately 0.06 and 0.08 inches, between approximately 0.065 and 0.075 inches, or between 0.068 and 0.073 inches. In some embodiments, the inner diameter is approximately 0.071 inches. In some embodiments, the distal most portion may taper to a decreased inner diameter as described elsewhere herein. The taper may occur approximately between the distal highly flexible portion and the transition region (e.g., over the most proximal portion of the distal highly flexible portion). The taper may be relatively gradual (e.g., occurring over approximately 10 or more cm) or may be relatively steep (e.g., occurring over less than approximately 5 cm). The inner diameter may taper to an inner diameter between about 0.03 and 0.06 inches. For example, the inner diameter may be about 0.035 inches, about 0.045 inches, or about 0.055 inches at the distal end of the catheter 3000. In some embodiments, the inner diameter may remain constant, at least over the catheter extension segment. In some embodiments, the coil 3024 may extend from a distal end of the catheter 3000 along the highly flexible distal portion ending at the distal end of the transition region. In other embodiments, the coil 3024 may extend from a distal end of the catheter to the proximal end of the transition region, to a point along the transition region, or proximally beyond the transition region. In other embodiments, the coil 3024 may extend the entire length of the catheter 3000 or catheter extension segment as described elsewhere herein. The braid 3010, when present, may extend from the proximal end of the coil 3024 to the proximal end of the catheter 3000 or catheter extension segment.
The catheters of the present invention may be composed of any of a variety of biologically compatible polymeric resins having suitable characteristics when formed into the tubular catheter body segments. Exemplary materials include polyvinyl chloride, polyethers, polyamides, polyethylenes, polyurethanes, copolymers thereof, and the like. In one embodiment, both the proximal body segment 33 and distal body segment 34 will comprise a polyvinyl chloride (PVC), with the proximal body segment being formed from a relatively rigid PVC and the distal body segment being formed from a relatively flexible, supple PVC. Optionally, the proximal body segment may be reinforced with a metal or polymeric braid or other conventional reinforcing layer.
Although the present invention has been described in terms of certain preferred embodiments, it may be incorporated into other embodiments by persons of skill in the art in view of the disclosure herein. The scope of the invention is therefore not intended to be limited by the specific embodiments disclosed herein, but is intended to be defined by the full scope of the following claims.
It is understood that this disclosure, in many respects, is only illustrative of the numerous alternative device embodiments of the present invention. Changes may be made in the details, particularly in matters of shape, size, material and arrangement of various device components without exceeding the scope of the various embodiments of the invention. Those skilled in the art will appreciate that the exemplary embodiments and descriptions thereof are merely illustrative of the invention as a whole. While several principles of the invention are made clear in the exemplary embodiments described above, those skilled in the art will appreciate that modifications of the structure, arrangement, proportions, elements, materials and methods of use, may be utilized in the practice of the invention, and otherwise, which are particularly adapted to specific environments and operative requirements without departing from the scope of the invention. In addition, while certain features and elements have been described in connection with particular embodiments, those skilled in the art will appreciate that those features and elements can be combined with the other embodiments disclosed herein.
When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.
Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.
Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.
Although the terms “first” and “second” may be used herein to describe various features/elements (including steps), these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present invention.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising” means various components can be co-jointly employed in the methods and articles (e.g., compositions and apparatuses including device and methods). For example, the term “comprising” will be understood to imply the inclusion of any stated elements or steps but not the exclusion of any other elements or steps.
As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word “about” or “approximately,” even if the term does not expressly appear. The phrase “about” or “approximately” may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/−0.1% of the stated value (or range of values), +/−1% of the stated value (or range of values), +/−2% of the stated value (or range of values), +/−5% of the stated value (or range of values), +/−10% of the stated value (or range of values), etc. Any numerical values given herein should also be understood to include about or approximately that value, unless the context indicates otherwise. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Any numerical range recited herein is intended to include all sub-ranges subsumed therein. It is also understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “X” is disclosed the “less than or equal to X” as well as “greater than or equal to X” (e.g., where X is a numerical value) is also disclosed. It is also understood that the throughout the application, data is provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point “10” and a particular data point “15” are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
Although various illustrative embodiments are described above, any of a number of changes may be made to various embodiments without departing from the scope of the invention as described by the claims. For example, the order in which various described method steps are performed may often be changed in alternative embodiments, and in other alternative embodiments one or more method steps may be skipped altogether. Optional features of various device and system embodiments may be included in some embodiments and not in others. Therefore, the foregoing description is provided primarily for exemplary purposes and should not be interpreted to limit the scope of the invention as it is set forth in the claims.
The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. As mentioned, other embodiments may be utilized and derived there from, such that structural and logical substitutions and changes may be made without departing from the scope of this disclosure. Such embodiments of the inventive subject matter may be referred to herein individually or collectively by the term “invention” merely for convenience and without intending to voluntarily limit the scope of this application to any single invention or inventive concept, if more than one is, in fact, disclosed. Thus, although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiments shown. This disclosure is intended to cover any and all adaptations or variations of various embodiments. Combinations of the above embodiments, and other embodiments not specifically described herein, will be apparent to those of skill in the art upon reviewing the above description.
This application claims the benefit of U.S. Provisional Application No. 62/694,796, filed Jul. 6, 2018, the entirety of this application is hereby incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
3605750 | Sheridan et al. | Sep 1971 | A |
3884242 | Bazell et al. | May 1975 | A |
3890976 | Bazell et al. | Jun 1975 | A |
3965901 | Penny et al. | Jun 1976 | A |
4030503 | Clark, III | Jun 1977 | A |
4319580 | Colley et al. | Mar 1982 | A |
4611594 | Grayhack et al. | Sep 1986 | A |
4617019 | Fecht et al. | Oct 1986 | A |
4619274 | Morrison et al. | Oct 1986 | A |
4628168 | Nebergall et al. | Dec 1986 | A |
4762129 | Bonzel | Aug 1988 | A |
4762130 | Fogarty et al. | Aug 1988 | A |
4767399 | Bollish | Aug 1988 | A |
4810582 | Gould et al. | Mar 1989 | A |
4844064 | Thimsen et al. | Jul 1989 | A |
4898575 | Fischell et al. | Feb 1990 | A |
4923462 | Stevens | May 1990 | A |
5011488 | Ginsburg | Apr 1991 | A |
5040548 | Yock | Aug 1991 | A |
5103827 | Smith | Apr 1992 | A |
5120323 | Shockey et al. | Jun 1992 | A |
5217705 | Reno et al. | Jun 1993 | A |
5226909 | Evans et al. | Jul 1993 | A |
5234416 | Macaulay et al. | Aug 1993 | A |
5243997 | Uflacker | Sep 1993 | A |
5261916 | Engelson et al. | Nov 1993 | A |
5290247 | Crittenden | Mar 1994 | A |
5308327 | Heaven et al. | May 1994 | A |
5328472 | Steinke et al. | Jul 1994 | A |
5413560 | Solar | May 1995 | A |
5417697 | Wilk | May 1995 | A |
5423846 | Fischell | Jun 1995 | A |
5439445 | Kontos | Aug 1995 | A |
5441051 | Hileman et al. | Aug 1995 | A |
5454795 | Samson | Oct 1995 | A |
5466222 | Ressemann et al. | Nov 1995 | A |
5474563 | Myler et al. | Dec 1995 | A |
5527292 | Adams et al. | Jun 1996 | A |
5549119 | Solar | Aug 1996 | A |
5569178 | Henley | Oct 1996 | A |
5569277 | Evans et al. | Oct 1996 | A |
5591187 | Dekel | Jan 1997 | A |
5643254 | Scheldrup et al. | Jul 1997 | A |
5658263 | Dang et al. | Aug 1997 | A |
5662622 | Gore et al. | Sep 1997 | A |
5690613 | Verbeek | Nov 1997 | A |
5695483 | Samson | Dec 1997 | A |
5702373 | Samson | Dec 1997 | A |
5766191 | Trerotola | Jun 1998 | A |
5776141 | Klein et al. | Jul 1998 | A |
5827242 | Follmer | Oct 1998 | A |
5843103 | Wulfman | Dec 1998 | A |
5873882 | Straub et al. | Feb 1999 | A |
5876414 | Straub | Mar 1999 | A |
5885209 | Green | Mar 1999 | A |
5891114 | Chien et al. | Apr 1999 | A |
5895398 | Wensel | Apr 1999 | A |
5899892 | Mortier et al. | May 1999 | A |
5916192 | Nita et al. | Jun 1999 | A |
5935112 | Stevens | Aug 1999 | A |
5951539 | Nita | Sep 1999 | A |
6007530 | Dornhofer et al. | Dec 1999 | A |
6056837 | Lieber et al. | May 2000 | A |
6059745 | Gelbfish | May 2000 | A |
6090118 | McGuckin, Jr. | Jul 2000 | A |
6159230 | Samuels | Dec 2000 | A |
6165163 | Chien et al. | Dec 2000 | A |
6165199 | Barbut | Dec 2000 | A |
6171295 | Garabedian et al. | Jan 2001 | B1 |
6179859 | Bates | Jan 2001 | B1 |
6197014 | Samson et al. | Mar 2001 | B1 |
6206852 | Lee | Mar 2001 | B1 |
6217557 | Hakansson et al. | Apr 2001 | B1 |
6221038 | Brisken | Apr 2001 | B1 |
6228046 | Brisken | May 2001 | B1 |
6258052 | Milo | Jul 2001 | B1 |
6267783 | Letendre et al. | Jul 2001 | B1 |
6285903 | Rosenthal | Sep 2001 | B1 |
6355027 | Le et al. | Mar 2002 | B1 |
6394976 | Winston et al. | May 2002 | B1 |
6451036 | Heitzmann | Jun 2002 | B1 |
6451005 | Saitou et al. | Sep 2002 | B1 |
6458139 | Palmer et al. | Oct 2002 | B1 |
6468219 | Njemanze | Oct 2002 | B1 |
6482217 | Pintor et al. | Nov 2002 | B1 |
6511492 | Rosenbluth | Jan 2003 | B1 |
6524303 | Garibaldi et al. | Feb 2003 | B1 |
6520934 | Lee | Mar 2003 | B1 |
6533751 | Cragg | Mar 2003 | B2 |
6554820 | Wendlandt | Apr 2003 | B1 |
6554827 | Chandrasekaran et al. | Apr 2003 | B2 |
6558377 | Lee et al. | May 2003 | B2 |
6569148 | Bagaoisan et al. | May 2003 | B2 |
6579246 | Jacobsen et al. | Jun 2003 | B2 |
6582440 | Brumbach | Jun 2003 | B1 |
6591472 | Noone et al. | Jul 2003 | B1 |
6638268 | Niazi | Oct 2003 | B2 |
6666874 | Heitzmann | Dec 2003 | B2 |
6669670 | Muni et al. | Dec 2003 | B1 |
6719717 | Johnson et al. | Apr 2004 | B1 |
6776770 | Trerotola | Aug 2004 | B1 |
6824550 | Pintor et al. | Nov 2004 | B1 |
6977068 | Nair et al. | Dec 2005 | B1 |
7004954 | Voss et al. | Feb 2006 | B1 |
7008434 | Kurz et al. | Mar 2006 | B2 |
7029482 | Vargas | Apr 2006 | B1 |
7037267 | Lipson et al. | May 2006 | B1 |
7104979 | Jansen et al. | Sep 2006 | B2 |
7112298 | Kampa et al. | Sep 2006 | B2 |
7172620 | Gilson | Feb 2007 | B2 |
7175653 | Gaber | Feb 2007 | B2 |
7207980 | Christian et al. | Apr 2007 | B2 |
7223274 | Vargas | May 2007 | B2 |
7229461 | Chin et al. | Jun 2007 | B2 |
7232452 | Adams et al. | Jun 2007 | B2 |
7235088 | Pintor et al. | Jun 2007 | B2 |
7306585 | Ross | Dec 2007 | B2 |
7309334 | von Hoffmann | Dec 2007 | B2 |
7335216 | Bender | Feb 2008 | B2 |
7491210 | Dubrul et al. | Feb 2009 | B2 |
7507229 | Hewitt et al. | Mar 2009 | B2 |
7537568 | Moehring | May 2009 | B2 |
7558622 | Tran | Jul 2009 | B2 |
7601138 | Goebel et al. | Oct 2009 | B2 |
7678100 | Chin et al. | Mar 2010 | B2 |
7713227 | Wholey et al. | May 2010 | B2 |
7763196 | Goebel et al. | Jul 2010 | B2 |
7771358 | Moehring et al. | Aug 2010 | B2 |
7803136 | Schatz | Sep 2010 | B2 |
7837692 | Mulholland et al. | Nov 2010 | B2 |
7842055 | Pintor et al. | Nov 2010 | B2 |
7850623 | Griffin | Dec 2010 | B2 |
7905891 | Self | Mar 2011 | B2 |
7931659 | Bose et al. | Apr 2011 | B2 |
7938820 | Webster et al. | May 2011 | B2 |
7988646 | Taber | Aug 2011 | B2 |
8021351 | Boldenow et al. | Sep 2011 | B2 |
8048032 | Root et al. | Nov 2011 | B2 |
8057497 | Raju et al. | Nov 2011 | B1 |
8062316 | Patel | Nov 2011 | B2 |
8070694 | Galdonik et al. | Dec 2011 | B2 |
8084246 | Hoon et al. | Dec 2011 | B2 |
8114106 | Straub | Feb 2012 | B2 |
8142413 | Root et al. | Mar 2012 | B2 |
8114032 | Ferry et al. | Apr 2012 | B2 |
8157792 | Dolliver et al. | Apr 2012 | B2 |
8211023 | Swan et al. | Jul 2012 | B2 |
8235968 | Tremaglio | Aug 2012 | B2 |
8246641 | Osborne et al. | Aug 2012 | B2 |
8292850 | Root et al. | Oct 2012 | B2 |
8298591 | Srivastava et al. | Oct 2012 | B2 |
8361095 | Osborne | Jan 2013 | B2 |
8366735 | Bose et al. | Feb 2013 | B2 |
8382739 | Walak et al. | Feb 2013 | B2 |
8394078 | Torrance et al. | Mar 2013 | B2 |
8403912 | McFerran et al. | Mar 2013 | B2 |
8460312 | Bose et al. | Jun 2013 | B2 |
8485969 | Grayzel et al. | Jul 2013 | B2 |
8517955 | Keast | Aug 2013 | B2 |
8535293 | Faherty et al. | Sep 2013 | B2 |
8568432 | Straub | Oct 2013 | B2 |
8608754 | Wensel et al. | Dec 2013 | B2 |
8609426 | Silver | Dec 2013 | B2 |
8663259 | Levine et al. | Mar 2014 | B2 |
8682411 | Kassab et al. | Mar 2014 | B2 |
8684963 | Qiu et al. | Apr 2014 | B2 |
8696698 | Chomas | Apr 2014 | B2 |
8702680 | Jimenez et al. | Apr 2014 | B2 |
8725249 | Bar-Yoseph et al. | May 2014 | B2 |
8734374 | Aklog et al. | May 2014 | B2 |
8758325 | Webster et al. | Jun 2014 | B2 |
8764779 | Levine et al. | Jul 2014 | B2 |
8814892 | Galdonik et al. | Aug 2014 | B2 |
8864792 | Eckhouse | Oct 2014 | B2 |
8876854 | Christiansen et al. | Nov 2014 | B2 |
8900257 | Straub et al. | Dec 2014 | B2 |
8932320 | Janardhan et al. | Jan 2015 | B1 |
RE45380 | Root et al. | Feb 2015 | E |
8968383 | Johnson et al. | Mar 2015 | B1 |
8974411 | McKinnon | Mar 2015 | B2 |
8992506 | Gulachenski | Mar 2015 | B2 |
8996095 | Anderson et al. | Mar 2015 | B2 |
8998946 | Morero et al. | Apr 2015 | B2 |
9014786 | Carmeli et al. | Apr 2015 | B2 |
9017309 | Tanikawa et al. | Apr 2015 | B2 |
9023070 | Levine et al. | May 2015 | B2 |
9039715 | Diamant et al. | May 2015 | B2 |
9079000 | Hanson et al. | Jul 2015 | B2 |
9107691 | Fojtik | Aug 2015 | B2 |
9119625 | Bachman et al. | Sep 2015 | B2 |
9119656 | Bose et al. | Sep 2015 | B2 |
9144383 | Zharov | Sep 2015 | B2 |
9144662 | DiCaprio et al. | Sep 2015 | B2 |
RE45760 | Root et al. | Oct 2015 | E |
RE45776 | Root et al. | Oct 2015 | E |
9199064 | Morero | Dec 2015 | B2 |
9238124 | Grayzel et al. | Jan 2016 | B2 |
9241699 | Kume et al. | Jan 2016 | B1 |
9259215 | Chou et al. | Feb 2016 | B2 |
9259228 | Cruise et al. | Feb 2016 | B2 |
9265512 | Garrison et al. | Feb 2016 | B2 |
9278201 | Rapaport et al. | Mar 2016 | B2 |
9282992 | Levine et al. | Mar 2016 | B2 |
9295817 | Chang | Mar 2016 | B2 |
9314268 | Cahill | Apr 2016 | B2 |
9345856 | Witte | May 2016 | B2 |
9351993 | Cruise et al. | May 2016 | B2 |
9370639 | Plassman et al. | Jun 2016 | B2 |
9375223 | Wallace | Jun 2016 | B2 |
9381278 | Constant et al. | Jul 2016 | B2 |
9399118 | Kume et al. | Jul 2016 | B2 |
RE46116 | Root et al. | Aug 2016 | E |
9408916 | Cruise et al. | Aug 2016 | B2 |
9414819 | Fitz et al. | Aug 2016 | B2 |
9421328 | Brueckner et al. | Aug 2016 | B2 |
9439791 | Vong et al. | Sep 2016 | B2 |
9440018 | Levin et al. | Sep 2016 | B2 |
9446216 | Olesky et al. | Sep 2016 | B2 |
9451884 | Palovich | Sep 2016 | B2 |
9451963 | Cruise et al. | Sep 2016 | B2 |
9463006 | Forde et al. | Oct 2016 | B2 |
9480813 | Fukuoka et al. | Nov 2016 | B2 |
9486221 | Cruise et al. | Nov 2016 | B2 |
9492637 | Garrison et al. | Nov 2016 | B2 |
9504476 | Gulachenski | Nov 2016 | B2 |
9510855 | Rapaport et al. | Dec 2016 | B2 |
9526504 | Chang | Dec 2016 | B2 |
9526505 | Marks et al. | Dec 2016 | B2 |
9532792 | Galdonik et al. | Jan 2017 | B2 |
9533344 | Monetti et al. | Jan 2017 | B2 |
9539022 | Bowman | Jan 2017 | B2 |
9539122 | Burke et al. | Jan 2017 | B2 |
9546236 | Cruise et al. | Jan 2017 | B2 |
9561121 | Sudin et al. | Feb 2017 | B2 |
9561125 | Bowman et al. | Feb 2017 | B2 |
9561345 | Garrison et al. | Feb 2017 | B2 |
9597101 | Galdonik et al. | Mar 2017 | B2 |
9597212 | Thompson et al. | Mar 2017 | B2 |
9615832 | Bose et al. | Mar 2017 | B2 |
9622753 | Cox | Apr 2017 | B2 |
9623228 | Ryan et al. | Apr 2017 | B2 |
9655633 | Leynov et al. | May 2017 | B2 |
9655755 | Chou et al. | May 2017 | B2 |
9655989 | Cruise et al. | May 2017 | B2 |
9662118 | Chang | May 2017 | B2 |
9662129 | Galdonik et al. | May 2017 | B2 |
9662480 | Kume et al. | May 2017 | B2 |
9669183 | Chang | Jun 2017 | B2 |
9669191 | Chou et al. | Jun 2017 | B2 |
9681882 | Garrison et al. | Jun 2017 | B2 |
9688788 | Plotkin et al. | Jun 2017 | B2 |
9693789 | Garrison et al. | Jul 2017 | B2 |
9693852 | Lam et al. | Jul 2017 | B2 |
9707380 | Qiu et al. | Jul 2017 | B2 |
9717500 | Tieu et al. | Aug 2017 | B2 |
9724103 | Cruise et al. | Aug 2017 | B2 |
9724491 | Solar et al. | Aug 2017 | B2 |
9764111 | Gulachenski | Sep 2017 | B2 |
9770251 | Bowman et al. | Sep 2017 | B2 |
9789242 | Criado et al. | Sep 2017 | B2 |
9775730 | Waltzman | Oct 2017 | B1 |
9789283 | Richter et al. | Oct 2017 | B2 |
9801643 | Hansen et al. | Oct 2017 | B2 |
9803043 | Cruise et al. | Oct 2017 | B2 |
9808610 | Li et al. | Nov 2017 | B2 |
9820761 | Garrison et al. | Nov 2017 | B2 |
9827047 | Fudaba et al. | Nov 2017 | B2 |
9855072 | Moberg et al. | Jan 2018 | B2 |
9861783 | Garrison et al. | Jan 2018 | B2 |
9877731 | Cruise et al. | Jan 2018 | B2 |
9907880 | Cruise et al. | Jan 2018 | B2 |
9883885 | Hendrick et al. | Feb 2018 | B2 |
9913960 | Blanchard et al. | Mar 2018 | B2 |
9987028 | Lowinger et al. | Jun 2018 | B2 |
9999355 | Kirenko | Jun 2018 | B2 |
10010698 | Watanabe et al. | Jul 2018 | B2 |
10028854 | Tatalovich et al. | Jul 2018 | B2 |
10039906 | Kume et al. | Aug 2018 | B2 |
10070878 | Ma | Sep 2018 | B2 |
10086169 | Grayzel et al. | Oct 2018 | B2 |
10105154 | Green | Oct 2018 | B1 |
10179224 | Yang et al. | Jan 2019 | B2 |
10183145 | Yang et al. | Jan 2019 | B2 |
10183146 | Yang et al. | Jan 2019 | B2 |
10183147 | Yang et al. | Jan 2019 | B2 |
10207077 | Griggin et al. | Feb 2019 | B2 |
10213582 | Garrison et al. | Feb 2019 | B2 |
10226277 | Smith et al. | Mar 2019 | B2 |
10238833 | Christian et al. | Mar 2019 | B2 |
10258452 | Eckhouse et al. | Apr 2019 | B2 |
10265086 | Vale et al. | Apr 2019 | B2 |
10271864 | Greenhalgh et al. | Apr 2019 | B2 |
10278678 | Peliks | May 2019 | B2 |
10278816 | Miller et al. | May 2019 | B2 |
10327790 | Garrison et al. | Jun 2019 | B2 |
10335186 | Rosenbluth et al. | Jul 2019 | B2 |
10342570 | Richter et al. | Jul 2019 | B2 |
10383691 | Hendrick et al. | Aug 2019 | B2 |
10384034 | Garrison et al. | Aug 2019 | B2 |
10420581 | Hehrlein et al. | Sep 2019 | B2 |
10441745 | Yang et al. | Oct 2019 | B2 |
10456552 | Goyal | Oct 2019 | B2 |
10471233 | Garrison et al. | Nov 2019 | B2 |
10524814 | Chang et al. | Jan 2020 | B2 |
10531883 | Deville et al. | Jan 2020 | B1 |
10537706 | Kanemasa et al. | Jan 2020 | B2 |
10569049 | Garrison et al. | Feb 2020 | B2 |
10610668 | Burkholz et al. | Apr 2020 | B2 |
10646239 | Garrison et al. | May 2020 | B2 |
10653434 | Yang et al. | May 2020 | B1 |
10668192 | Raney et al. | Jun 2020 | B2 |
10695159 | Hauser | Jun 2020 | B2 |
10716880 | Culbert et al. | Jul 2020 | B2 |
10716915 | Ogle et al. | Jul 2020 | B2 |
10722251 | Garrison et al. | Jul 2020 | B2 |
10722253 | Deville et al. | Jul 2020 | B2 |
10722683 | Solar et al. | Jul 2020 | B2 |
10743893 | Garrison et al. | Aug 2020 | B2 |
10786270 | Yang | Sep 2020 | B2 |
10856898 | Matsushita et al. | Dec 2020 | B2 |
10888280 | Newberry | Jan 2021 | B2 |
10905850 | Christian et al. | Feb 2021 | B2 |
11020030 | Tao et al. | Jun 2021 | B2 |
11065018 | Buck et al. | Jul 2021 | B2 |
11076876 | Vale | Aug 2021 | B2 |
11197683 | Teigen et al. | Dec 2021 | B1 |
11207096 | To et al. | Dec 2021 | B2 |
11207497 | Yee et al. | Dec 2021 | B1 |
20010031980 | Wensel et al. | Oct 2001 | A1 |
20010031981 | Evans | Oct 2001 | A1 |
20010049486 | Evans et al. | Dec 2001 | A1 |
20020016565 | Zadno-Azizi et al. | Feb 2002 | A1 |
20020026145 | Bagaoisan et al. | Feb 2002 | A1 |
20020074276 | Nakashima | Jun 2002 | A1 |
20020091372 | Cragg | Jul 2002 | A1 |
20020156459 | Ye et al. | Oct 2002 | A1 |
20020156460 | Ye | Oct 2002 | A1 |
20020169467 | Heitzmann | Nov 2002 | A1 |
20020177899 | Eum et al. | Nov 2002 | A1 |
20020188314 | Anderson et al. | Dec 2002 | A1 |
20030088266 | Bowlin | May 2003 | A1 |
20030135193 | Hilgers et al. | Jul 2003 | A1 |
20030135198 | Berhow et al. | Jul 2003 | A1 |
20030153874 | Tal | Aug 2003 | A1 |
20030195467 | Mickley | Oct 2003 | A1 |
20030195546 | Solar et al. | Oct 2003 | A1 |
20030225336 | Callister et al. | Dec 2003 | A1 |
20040010280 | Adams et al. | Jan 2004 | A1 |
20040059290 | Palasis | Mar 2004 | A1 |
20040138693 | Eskuri | Jul 2004 | A1 |
20040153049 | Hewitt et al. | Aug 2004 | A1 |
20040199201 | Kellett | Oct 2004 | A1 |
20040236215 | Mihara et al. | Nov 2004 | A1 |
20040243102 | Berg et al. | Dec 2004 | A1 |
20050004523 | Osborne et al. | Jan 2005 | A1 |
20050004553 | Douk | Jan 2005 | A1 |
20050021002 | Deckman et al. | Jan 2005 | A1 |
20050055047 | Greenhalgh | Mar 2005 | A1 |
20050059957 | Campbell | Mar 2005 | A1 |
20050080400 | Corcoran et al. | Apr 2005 | A1 |
20050103332 | Gingles et al. | May 2005 | A1 |
20050137680 | Ortiz et al. | Jun 2005 | A1 |
20050182386 | Aggerholm | Aug 2005 | A1 |
20060030835 | Sherman et al. | Feb 2006 | A1 |
20060064036 | Osborne et al. | Mar 2006 | A1 |
20060095062 | Stephens | May 2006 | A1 |
20060100530 | Kliot et al. | May 2006 | A1 |
20060111649 | Zhou | May 2006 | A1 |
20060124212 | Zhou | Jun 2006 | A1 |
20060149355 | Mitelberg et al. | Jul 2006 | A1 |
20060217664 | Hattler et al. | Sep 2006 | A1 |
20060247755 | Pal et al. | Nov 2006 | A1 |
20060264759 | Moehring et al. | Nov 2006 | A1 |
20070016132 | Oepen et al. | Jan 2007 | A1 |
20070043333 | Kampa et al. | Feb 2007 | A1 |
20070060888 | Goff et al. | Mar 2007 | A1 |
20070185521 | Bui et al. | Aug 2007 | A1 |
20070197956 | Le et al. | Aug 2007 | A1 |
20070225614 | Naghavi et al. | Sep 2007 | A1 |
20080064984 | Pflueger et al. | Mar 2008 | A1 |
20080086110 | Galdonik et al. | Apr 2008 | A1 |
20080097251 | Babaev et al. | Apr 2008 | A1 |
20080188928 | Salahieh et al. | Aug 2008 | A1 |
20080234715 | Pesce | Sep 2008 | A1 |
20080262350 | Unger | Oct 2008 | A1 |
20080300544 | Palm et al. | Dec 2008 | A1 |
20080312639 | Weber | Dec 2008 | A1 |
20090030400 | Bose et al. | Jan 2009 | A1 |
20090043330 | To | Feb 2009 | A1 |
20090182370 | Volobuyev et al. | Jul 2009 | A1 |
20090187143 | Vreeman | Jul 2009 | A1 |
20090209857 | Secretain et al. | Aug 2009 | A1 |
20090210048 | Amplatz et al. | Aug 2009 | A1 |
20090227992 | Nir et al. | Sep 2009 | A1 |
20090234321 | Shapland et al. | Sep 2009 | A1 |
20090264865 | Kawai | Oct 2009 | A1 |
20090270888 | Patel | Oct 2009 | A1 |
20090275974 | Marchand et al. | Nov 2009 | A1 |
20090312699 | Pudelko | Dec 2009 | A1 |
20100030256 | Dubrul et al. | Feb 2010 | A1 |
20100049168 | Parker et al. | Feb 2010 | A1 |
20100057051 | Howat et al. | Mar 2010 | A1 |
20100114017 | Lenker et al. | May 2010 | A1 |
20100125253 | Olson et al. | May 2010 | A1 |
20100217235 | Thorstenson et al. | Aug 2010 | A1 |
20100217276 | Garrison et al. | Aug 2010 | A1 |
20100312141 | Keast et al. | Dec 2010 | A1 |
20110009875 | Grandfield et al. | Jan 2011 | A1 |
20110034986 | Chou | Feb 2011 | A1 |
20110054504 | Porter | Mar 2011 | A1 |
20110082373 | Gurley et al. | Apr 2011 | A1 |
20110106200 | Ziegler | May 2011 | A1 |
20110137399 | Chomas et al. | Jun 2011 | A1 |
20110152998 | Berez et al. | Jun 2011 | A1 |
20110172700 | Bose et al. | Jul 2011 | A1 |
20110178418 | Avidor et al. | Jul 2011 | A1 |
20110230859 | Galdonik et al. | Sep 2011 | A1 |
20110238041 | Lim et al. | Sep 2011 | A1 |
20110295217 | Tanaka et al. | Dec 2011 | A1 |
20120040858 | Ford et al. | Feb 2012 | A1 |
20120041474 | Eckhouse | Feb 2012 | A1 |
20120065479 | Lahiji et al. | Mar 2012 | A1 |
20120065490 | Zharov et al. | Mar 2012 | A1 |
20120078140 | Nita | Mar 2012 | A1 |
20120083868 | Shrivastava et al. | Apr 2012 | A1 |
20120123327 | Miller | May 2012 | A1 |
20120143237 | Cam et al. | Jun 2012 | A1 |
20120150147 | Leynov et al. | Jun 2012 | A1 |
20120290067 | Cam et al. | Nov 2012 | A1 |
20120330196 | Nita | Dec 2012 | A1 |
20130006225 | Cucin | Jan 2013 | A1 |
20130018318 | Ravichandran et al. | Jan 2013 | A1 |
20130018359 | Coyle | Jan 2013 | A1 |
20130035628 | Garrison et al. | Feb 2013 | A1 |
20130046285 | Griffin et al. | Feb 2013 | A1 |
20130046374 | Jones-McMeans | Feb 2013 | A1 |
20130116701 | Wang et al. | May 2013 | A1 |
20130131641 | Jimenez et al. | May 2013 | A1 |
20130131710 | Carmeli | May 2013 | A1 |
20130158578 | Ghodke et al. | Jun 2013 | A1 |
20140025043 | Wang et al. | Jan 2014 | A1 |
20140074144 | Shrivastava et al. | Mar 2014 | A1 |
20140114287 | Beasley et al. | Apr 2014 | A1 |
20140121746 | Kusleika et al. | May 2014 | A1 |
20140155932 | Bose et al. | Jun 2014 | A1 |
20140155980 | Turjman et al. | Jun 2014 | A1 |
20140163367 | Eskuri | Jun 2014 | A1 |
20140228808 | Webster et al. | Aug 2014 | A1 |
20140243882 | Ma | Aug 2014 | A1 |
20140249508 | Wang et al. | Sep 2014 | A1 |
20140271718 | Alvarez | Sep 2014 | A1 |
20140273920 | Smith | Sep 2014 | A1 |
20140275832 | Muehlsteff et al. | Sep 2014 | A1 |
20140275852 | Hong et al. | Sep 2014 | A1 |
20140276167 | Dasgupta et al. | Sep 2014 | A1 |
20140276618 | Di Caprio | Sep 2014 | A1 |
20140276920 | Hendrick et al. | Sep 2014 | A1 |
20140276923 | Miller | Sep 2014 | A1 |
20140288525 | Fudaba et al. | Sep 2014 | A1 |
20140296889 | Avneri et al. | Oct 2014 | A1 |
20140309533 | Yamashita et al. | Oct 2014 | A1 |
20140330286 | Wallace | Nov 2014 | A1 |
20140343537 | Eversull et al. | Nov 2014 | A1 |
20140350645 | Diller et al. | Nov 2014 | A1 |
20140358123 | Ueda | Dec 2014 | A1 |
20140371718 | Alvarez et al. | Dec 2014 | A1 |
20150005704 | Heisel et al. | Jan 2015 | A1 |
20150046148 | Oh et al. | Feb 2015 | A1 |
20150105729 | Valeti et al. | Apr 2015 | A1 |
20150119859 | Cajamarca et al. | Apr 2015 | A1 |
20150126861 | Gambhir et al. | May 2015 | A1 |
20150133978 | Paul, Jr. | May 2015 | A1 |
20150157220 | Fish et al. | Jun 2015 | A1 |
20150157772 | Li et al. | Jun 2015 | A1 |
20150173782 | Garrison et al. | Jun 2015 | A1 |
20150174363 | Sutermeister et al. | Jun 2015 | A1 |
20150257659 | Broers et al. | Sep 2015 | A1 |
20150269825 | Tran | Sep 2015 | A1 |
20150290390 | Ring et al. | Oct 2015 | A1 |
20150335288 | Toth et al. | Nov 2015 | A1 |
20150335857 | Ishikawa | Nov 2015 | A1 |
20150359547 | Vale | Dec 2015 | A1 |
20150366518 | Sampson | Dec 2015 | A1 |
20160000443 | Lilburn et al. | Jan 2016 | A1 |
20160008572 | Di Caprio | Jan 2016 | A1 |
20160030079 | Cohen | Feb 2016 | A1 |
20160038174 | Bruzzi et al. | Feb 2016 | A1 |
20160051386 | Haarmann-Theimann | Feb 2016 | A1 |
20160058459 | Bowman | Mar 2016 | A1 |
20160081825 | Sudin et al. | Mar 2016 | A1 |
20160100819 | Tieu | Apr 2016 | A1 |
20160128688 | Garrison et al. | May 2016 | A1 |
20160129221 | Haverkost et al. | May 2016 | A1 |
20160135829 | Holochwost et al. | May 2016 | A1 |
20160144157 | Gulachenski et al. | May 2016 | A1 |
20160151010 | Erez | Jun 2016 | A1 |
20160166265 | Nita | Jun 2016 | A1 |
20160166266 | Nita | Jun 2016 | A1 |
20160199204 | Pung et al. | Jul 2016 | A1 |
20160199620 | Pokorney | Jul 2016 | A1 |
20160206216 | Kirenko | Jul 2016 | A1 |
20160206322 | Fitz et al. | Jul 2016 | A1 |
20160213396 | Dowell et al. | Jul 2016 | A1 |
20160220741 | Garrison et al. | Aug 2016 | A1 |
20160242764 | Garrison et al. | Aug 2016 | A1 |
20160242893 | Joshi et al. | Aug 2016 | A1 |
20160243157 | Cruise et al. | Aug 2016 | A1 |
20160256611 | Fitz | Sep 2016 | A1 |
20160270806 | Wallace | Sep 2016 | A1 |
20160271315 | Chang | Sep 2016 | A1 |
20160296690 | Kume et al. | Oct 2016 | A1 |
20160311990 | Cruise et al. | Oct 2016 | A1 |
20160317156 | Fitz et al. | Nov 2016 | A1 |
20160317288 | Rogers et al. | Nov 2016 | A1 |
20160345904 | Bowman | Dec 2016 | A1 |
20160346508 | Williams et al. | Dec 2016 | A1 |
20160346515 | Buller | Dec 2016 | A1 |
20160354532 | Olesky et al. | Dec 2016 | A1 |
20160361180 | Vong et al. | Dec 2016 | A1 |
20160361459 | Baldwin | Dec 2016 | A1 |
20160367274 | Wallace | Dec 2016 | A1 |
20160367275 | Wallace | Dec 2016 | A1 |
20170007264 | Cruise et al. | Jan 2017 | A1 |
20170007277 | Drapeau et al. | Jan 2017 | A1 |
20170020540 | Chou et al. | Jan 2017 | A1 |
20170027604 | Wallace | Feb 2017 | A1 |
20170028170 | Ho | Feb 2017 | A1 |
20170035436 | Morita | Feb 2017 | A1 |
20170035446 | Rapaport et al. | Feb 2017 | A1 |
20170042548 | Lam | Feb 2017 | A1 |
20170043124 | Vreeman | Feb 2017 | A1 |
20170056061 | Ogle et al. | Mar 2017 | A1 |
20170071624 | McGuckin et al. | Mar 2017 | A1 |
20170072163 | Lim et al. | Mar 2017 | A1 |
20170072165 | Lim et al. | Mar 2017 | A1 |
20170072452 | Monetti et al. | Mar 2017 | A1 |
20170079680 | Bowman | Mar 2017 | A1 |
20170079812 | Lam et al. | Mar 2017 | A1 |
20170079817 | Sepetka et al. | Mar 2017 | A1 |
20170079819 | Pung et al. | Mar 2017 | A1 |
20170079820 | Lam et al. | Mar 2017 | A1 |
20170087340 | Peralta et al. | Mar 2017 | A1 |
20170100126 | Bowman et al. | Apr 2017 | A1 |
20170100142 | Look | Apr 2017 | A1 |
20170105743 | Vale et al. | Apr 2017 | A1 |
20170143938 | Ogle | May 2017 | A1 |
20170147765 | Mehta | May 2017 | A1 |
20170164964 | Galdonik et al. | Jun 2017 | A1 |
20170172581 | Bose et al. | Jun 2017 | A1 |
20170172766 | Vong et al. | Jun 2017 | A1 |
20170181835 | Kleshinski et al. | Jun 2017 | A1 |
20170189033 | Sepetka et al. | Jul 2017 | A1 |
20170209260 | Garrison et al. | Jul 2017 | A1 |
20170215902 | Leynov et al. | Aug 2017 | A1 |
20170216484 | Cruise et al. | Aug 2017 | A1 |
20170224350 | Shimizu et al. | Aug 2017 | A1 |
20170224355 | Bowman et al. | Aug 2017 | A1 |
20170224953 | Tran et al. | Aug 2017 | A1 |
20170238950 | Yang et al. | Aug 2017 | A1 |
20170238953 | Yang et al. | Aug 2017 | A1 |
20170246014 | Rapaport et al. | Aug 2017 | A1 |
20170252057 | Bonnette et al. | Sep 2017 | A1 |
20170259037 | Kern et al. | Sep 2017 | A1 |
20170265869 | Cibulski et al. | Sep 2017 | A1 |
20170265983 | Lam et al. | Sep 2017 | A1 |
20170274180 | Garrison et al. | Sep 2017 | A1 |
20170281192 | Tieu et al. | Oct 2017 | A1 |
20170281204 | Garrison et al. | Oct 2017 | A1 |
20170283536 | Cruise et al. | Oct 2017 | A1 |
20170303949 | Jacobi et al. | Oct 2017 | A1 |
20170340867 | Accisano | Nov 2017 | A1 |
20170348514 | Guyon et al. | Dec 2017 | A1 |
20170354421 | Maguire et al. | Dec 2017 | A1 |
20170354523 | Chou et al. | Dec 2017 | A1 |
20170354803 | Kume et al. | Dec 2017 | A1 |
20170360450 | Tompkins et al. | Dec 2017 | A1 |
20170361072 | Chou | Dec 2017 | A1 |
20170367713 | Green et al. | Dec 2017 | A1 |
20170367857 | Bennett et al. | Dec 2017 | A1 |
20170368296 | Chang | Dec 2017 | A1 |
20170368309 | Garrison et al. | Dec 2017 | A1 |
20180008294 | Garrison et al. | Jan 2018 | A1 |
20180008439 | Tieu et al. | Jan 2018 | A9 |
20180014840 | Paniam | Jan 2018 | A1 |
20180028205 | Chou et al. | Feb 2018 | A1 |
20180028209 | Sudin et al. | Feb 2018 | A1 |
20180036155 | Tieu et al. | Feb 2018 | A1 |
20180042623 | Batiste | Feb 2018 | A1 |
20180055364 | Pierro | Mar 2018 | A1 |
20180055516 | Bagaoisan et al. | Mar 2018 | A1 |
20180104390 | Kilcran | Apr 2018 | A1 |
20180193026 | Yang | Jul 2018 | A1 |
20180200478 | Lorenzo et al. | Jul 2018 | A1 |
20180207395 | Bulman et al. | Jul 2018 | A1 |
20180207399 | Chou et al. | Jul 2018 | A1 |
20180228502 | Shaffer | Aug 2018 | A1 |
20180242962 | Walen et al. | Aug 2018 | A1 |
20180242980 | Lubock | Aug 2018 | A1 |
20180242989 | Nita | Aug 2018 | A1 |
20180242999 | Thatipelli | Aug 2018 | A1 |
20180250013 | Wallace et al. | Sep 2018 | A1 |
20180263632 | Seifert et al. | Sep 2018 | A1 |
20180263642 | Nita | Sep 2018 | A1 |
20180279965 | Pandit et al. | Oct 2018 | A1 |
20180289340 | Trindade Rodrigues et al. | Oct 2018 | A1 |
20180296236 | Goldfarb et al. | Oct 2018 | A1 |
20180353194 | Shaffer et al. | Dec 2018 | A1 |
20190022363 | Grayzel et al. | Jan 2019 | A1 |
20190029825 | Fitterer et al. | Jan 2019 | A1 |
20190070387 | Goyal | Mar 2019 | A1 |
20190108540 | Look et al. | Apr 2019 | A1 |
20190167124 | Verkruijsse et al. | Jun 2019 | A1 |
20190175030 | Verkruijsse et al. | Jun 2019 | A1 |
20190200871 | De Haan | Jul 2019 | A1 |
20190239910 | Brade et al. | Aug 2019 | A1 |
20190275290 | Yamashita et al. | Sep 2019 | A1 |
20190290884 | Kanemasa et al. | Sep 2019 | A1 |
20190329003 | Watanabe | Oct 2019 | A1 |
20190336142 | Torrie | Nov 2019 | A1 |
20190336149 | Yang | Nov 2019 | A1 |
20190336727 | Yang | Nov 2019 | A1 |
20190351182 | Chou et al. | Nov 2019 | A1 |
20190366041 | Yang | Dec 2019 | A1 |
20200001046 | Yang | Jan 2020 | A1 |
20200009301 | Yee | Jan 2020 | A1 |
20200009350 | Goyal | Jan 2020 | A1 |
20200022712 | Deville et al. | Jan 2020 | A1 |
20200023160 | Chou et al. | Jan 2020 | A1 |
20200046368 | Merritt et al. | Feb 2020 | A1 |
20200046937 | Nakagawa et al. | Feb 2020 | A1 |
20200170521 | Gupta et al. | Jun 2020 | A1 |
20200171276 | Onozuka | Jun 2020 | A1 |
20200171277 | Garrison et al. | Jun 2020 | A1 |
20200188630 | Fujita et al. | Jun 2020 | A1 |
20200025845 | Yang et al. | Jul 2020 | A1 |
20200205845 | Yang et al. | Jul 2020 | A1 |
20200276411 | Ogle et al. | Sep 2020 | A1 |
20200289136 | Chou | Sep 2020 | A1 |
20200297362 | Devill et al. | Sep 2020 | A1 |
20200297972 | Yee | Sep 2020 | A1 |
20200306501 | Yee | Oct 2020 | A1 |
20200323535 | Yang | Oct 2020 | A1 |
20200337716 | Garrison et al. | Oct 2020 | A1 |
20200345979 | Loh et al. | Nov 2020 | A1 |
20210001141 | Pfiffner et al. | Jan 2021 | A1 |
20210045758 | Garrison et al. | Feb 2021 | A1 |
20210052296 | Garrison | Feb 2021 | A1 |
20210068852 | Spence | Mar 2021 | A1 |
20210093336 | Roue | Apr 2021 | A1 |
20210106238 | Strasser | Apr 2021 | A1 |
20210106792 | Rafiee | Apr 2021 | A1 |
20210128182 | Teigen et al. | May 2021 | A1 |
20210146094 | Christian et al. | May 2021 | A1 |
20210153744 | Pierro | May 2021 | A1 |
20210186537 | Buck et al. | Jun 2021 | A1 |
20210186542 | Buck et al. | Jun 2021 | A1 |
20210187244 | Buck et al. | Jun 2021 | A1 |
20210315596 | Buck et al. | Oct 2021 | A1 |
20210315597 | Buck et al. | Oct 2021 | A1 |
20210315598 | Buck et al. | Oct 2021 | A1 |
20210316121 | Buck et al. | Oct 2021 | A1 |
20210316127 | Buck et al. | Oct 2021 | A1 |
20210361366 | Murphy et al. | Nov 2021 | A1 |
20210361909 | Cottone et al. | Nov 2021 | A1 |
20210378527 | Strasser et al. | Dec 2021 | A1 |
20210378696 | Yang et al. | Dec 2021 | A1 |
20220047849 | Yee et al. | Feb 2022 | A1 |
20220211975 | Yang et al. | Jul 2022 | A1 |
Number | Date | Country |
---|---|---|
110916768 | Mar 2020 | CN |
8900059 | May 1989 | DE |
10 2010 053111 | Jun 2012 | DE |
10 2012 112732 | Jun 2014 | DE |
0 330 843 | Dec 1993 | EP |
0 582 533 | Feb 1994 | EP |
0 309 471 | Aug 1996 | EP |
1 349 486 | Mar 2008 | EP |
2 069 528 | Mar 2013 | EP |
2 937 108 | Oct 2015 | EP |
2 928 360 | Jan 2017 | EP |
2 211 732 | May 2018 | EP |
3 539 486 | Sep 2019 | EP |
3 698 740 | Aug 2020 | EP |
2077132 | Dec 1981 | GB |
2002-535049 | Oct 2002 | JP |
2003-527925 | Sep 2003 | JP |
2006-102222 | Apr 2006 | JP |
2006-521881 | Sep 2006 | JP |
2008-502378 | Jan 2008 | JP |
2013-504388 | Feb 2013 | JP |
2014-515670 | Jul 2014 | JP |
2015-504327 | Feb 2015 | JP |
WO 1995009659 | Apr 1995 | WO |
WO 2000000100 | Jan 2000 | WO |
WO 2009054968 | Apr 2009 | WO |
WO 2009132218 | Oct 2009 | WO |
WO 2010126786 | Nov 2010 | WO |
WO 2014151209 | Sep 2014 | WO |
WO 2014203336 | Dec 2014 | WO |
WO 2017025775 | Feb 2017 | WO |
WO 2018121363 | Jul 2018 | WO |
WO 2019178165 | Sep 2019 | WO |
WO 2019222518 | Nov 2019 | WO |
WO 2019246583 | Dec 2019 | WO |
WO 2020145928 | Jul 2020 | WO |
WO 2021016213 | Jan 2021 | WO |
WO 2021064955 | Apr 2021 | WO |
WO 2021090821 | May 2021 | WO |
WO 2021105658 | Jun 2021 | WO |
WO 2021242734 | Dec 2021 | WO |
Entry |
---|
Guidezilla Guide Extension Catheter, Boston Scientific 510k Submission, Feb. 20, 2017. |
International Search Report and Written Opinion dated Sep. 30, 2019 in Application No. PCT/US19/040691. |
Merit Medical Systems Acquired Distal Access's SPINR Platform, Jul. 15, 2015, Digital Access, LLC; Merit Medical Systems, 5 pages. |
Simon et al., Exploring the efficacy of cyclic vs. static aspiration in a cerebral thrombectomy model: an initial proof of concept study, J. NeuroInvent Surg 2014, 6 pp. 677-683. |
Simon et al., Hydrodynamic comparison of the Penumbra system and commonly available syringes in forced-suction thrombectomy, J. NeuroInvent Surg 2014, 6, pp. 205-211. |
Spiotta et al., Evolution of thrombectomy approaches and devices for acute stroke: a technical review, J. Neuro Intervent Surg 2015, 7, pp. 2-7. |
Abay et al., 2014, Investigation of photoplethysmography and Near Infrared Spectroscopy for the assessment of tissue blood perfusion, 36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Chicago, IL, pp. 5361-5364, doi: 10.1109/EMBC.2014.6944837. |
Korpelainen et al., 1995, Asymmetrical skin temperature in ischemic stroke, Stroke, 26(9):1543-1547. |
Bernava et al., Sep. 23, 2019, Direct trhomboaspiration efficacy for mechanical thrombectomy is related to the angle of interaction between the catheter and the clot, J. NeuroIntervent Surg., 0:1-6, doi:10.1136/neurintsurg-2019-015113. |
Number | Date | Country | |
---|---|---|---|
20200008820 A1 | Jan 2020 | US |
Number | Date | Country | |
---|---|---|---|
62694796 | Jul 2018 | US |